{"b48877986dffbf8d8219c2099c681633964a2d19": [["CorrespondenceIntrapartum care of women with COVID-19: A practical approach Dear Editor, Obstetricians have steadily fought to improve outcomes for women over the past 3 decades, with the application of evidencebased medicine.", [["women", "ORGANISM", 34, 39], ["women", "ORGANISM", 148, 153], ["women", "SPECIES", 34, 39], ["women", "SPECIES", 148, 153], ["evidencebased medicine", "TREATMENT", 203, 225]]], ["The current COVID-19 pandemic has overwhelmed this standardized approach with a deluge of information, at times contradictory, leading to confusion in the labor ward regarding best practice.", [["confusion", "DISEASE", 138, 147], ["confusion", "PROBLEM", 138, 147]]], ["As community person-to-person transmission of the virus escalates, we will increasingly have to manage labor for COVID-19 positive patients.", [["patients", "ORGANISM", 131, 139], ["person", "SPECIES", 13, 19], ["person", "SPECIES", 23, 29], ["patients", "SPECIES", 131, 139], ["the virus escalates", "PROBLEM", 46, 65], ["labor", "PROBLEM", 103, 108], ["COVID", "TEST", 113, 118]]], ["This is based on recommendations issued by the International Society of Ultrasound in Obstetrics and Gynecology [1] , Royal College of Obstetricians and Gynaecologists [2] , Coll\u00e8ge National des Gyn\u00e9cologues et Obst\u00e9triciens Fran\u00e7ais [3] , and Society for Obstetric Anesthesia and Perinatology [4] .CorrespondenceMost of the recommendations highlighted in our bulletin are similar between the international bodies: multidisciplinary approach; mode of delivery as usually indicated; close monitoring of maternal vital signs; continuous fetal heart monitoring; conservative fluid therapy; oxygen therapy as needed; early neuraxial anesthesia; elective instrumental delivery according to maternal condition; and stabilization of the critically ill patient by specialists followed by cesarean section and appropriate protective measures.CorrespondenceHowever some discrepancies can be found between recommendations regarding the presence of birth partner, delayed umbilical cord clamping, separation of mother and baby, and use of nitrous oxide analgesia systems.", [["fetal", "ANATOMY", 535, 540], ["heart", "ANATOMY", 541, 546], ["fluid", "ANATOMY", 572, 577], ["neuraxial", "ANATOMY", 619, 628], ["umbilical cord", "ANATOMY", 960, 974], ["oxygen", "CHEMICAL", 587, 593], ["critically ill", "DISEASE", 730, 744], ["nitrous oxide", "CHEMICAL", 1027, 1040], ["oxygen", "CHEMICAL", 587, 593], ["nitrous oxide", "CHEMICAL", 1027, 1040], ["fetal heart", "MULTI-TISSUE_STRUCTURE", 535, 546], ["oxygen", "SIMPLE_CHEMICAL", 587, 593], ["patient", "ORGANISM", 745, 752], ["umbilical cord", "MULTI-TISSUE_STRUCTURE", 960, 974], ["nitrous oxide", "SIMPLE_CHEMICAL", 1027, 1040], ["patient", "SPECIES", 745, 752], ["Obstetric Anesthesia", "TREATMENT", 256, 276], ["multidisciplinary approach", "TREATMENT", 415, 441], ["delivery", "TREATMENT", 451, 459], ["maternal vital signs", "TEST", 502, 522], ["continuous fetal heart monitoring", "TEST", 524, 557], ["conservative fluid therapy", "TREATMENT", 559, 585], ["oxygen therapy", "TREATMENT", 587, 601], ["early neuraxial anesthesia", "TREATMENT", 613, 639], ["elective instrumental delivery", "TREATMENT", 641, 671], ["cesarean section", "TREATMENT", 780, 796], ["appropriate protective measures", "TREATMENT", 801, 832], ["some discrepancies", "PROBLEM", 855, 873], ["delayed umbilical cord clamping", "TREATMENT", 952, 983], ["nitrous oxide analgesia systems", "TREATMENT", 1027, 1058], ["heart", "ANATOMY", 541, 546], ["umbilical cord", "ANATOMY", 960, 974], ["clamping", "OBSERVATION", 975, 983]]], ["We have to keep in mind that our current knowledge on management of COVID-19 during pregnancy is based on small cohort studies, experience of similar viral pulmonary infections and expert consensus, which generate divergent recommendations.", [["pulmonary", "ANATOMY", 156, 165], ["COVID-19", "CHEMICAL", 68, 76], ["viral pulmonary infections", "DISEASE", 150, 176], ["COVID-19", "CHEMICAL", 68, 76], ["pulmonary", "ORGAN", 156, 165], ["COVID", "TEST", 68, 73], ["small cohort studies", "TEST", 106, 126], ["similar viral pulmonary infections", "PROBLEM", 142, 176], ["viral", "OBSERVATION_MODIFIER", 150, 155], ["pulmonary", "ANATOMY", 156, 165], ["infections", "OBSERVATION", 166, 176]]], ["Thus, guidelines will no doubt be adapted as we gather clinical data and experience.CorrespondenceDespite these anticipated developments, health care facilities should procure clear management protocols for care providers.", [["clear management protocols", "TREATMENT", 176, 202], ["care providers", "TREATMENT", 207, 221]]], ["Furthermore, it is also important for team members to undertake training in proper utilization of personal protective equipment and scenario simulation, such as emergency cesarean section, in order to ensure efficiency in patient care as well as protective measures.Declaration of Competing InterestWe declare no competing interest.", [["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 222, 229], ["personal protective equipment", "TREATMENT", 98, 127], ["scenario simulation", "TREATMENT", 132, 151], ["emergency cesarean section", "TREATMENT", 161, 187], ["protective measures", "TREATMENT", 246, 265]]]], "PMC7149882": [["EPIDEMIOLOGYMS is a common cause of neurological disability in middle-aged adults.", [["neurological", "ANATOMY", 36, 48], ["neurological disability", "DISEASE", 36, 59], ["adults", "ORGANISM", 75, 81], ["neurological disability", "PROBLEM", 36, 59]]], ["This disease affects over one million people worldwide and is very common within the USA (Minden et al., 1993; Pugliatti et al., 2002; O'Connor et al., 2002).", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["Age, sex, race, geographical latitude, genetics and environmental exposure are risk factors for developing MS.EPIDEMIOLOGYThe median age of onset of MS is approximately 24 years of age (Minden et al., 1993) with a female to male ratio of two to one (O'Connor et al., 2002).", [["MS", "DISEASE", 149, 151], ["MS", "PROBLEM", 149, 151]]], ["The mean age of death of MS patients is 58 years old, compared to the general national average in the USA of 72 years old (Minden et al., 1993).", [["death", "DISEASE", 16, 21], ["MS", "DISEASE", 25, 27], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]], ["Within the USA, MS is observed more often in Caucasians compared to African-Americans (Minden et al., 1993).", [["MS", "DISEASE", 16, 18]]], ["However, the typical clinical course is more severe within African-Americans who are affected (Pugliatti et al., 2002).", [["severe", "OBSERVATION_MODIFIER", 45, 51]]], ["In regard to geographical patterns, a higher incidence of MS occurs when moving either more north or south of the equator, especially in countries with colder climates (Pugliatti et al., 2002).", [["MS", "DISEASE", 58, 60], ["MS", "PROBLEM", 58, 60], ["higher", "OBSERVATION_MODIFIER", 38, 44]]], ["This latitude effect is also present within the USA as the incidence of MS is highest within the upper Midwest and Northeast compared to the South (Minden et al., 1993).EPIDEMIOLOGYFamily studies have shown that genetic factors contribute to MS (Sadovnick, 2002; Herrera and Ebers, 2003; Kenealy et al., 2003; Willer et al., 2003).", [["MS", "DISEASE", 72, 74], ["MS", "DISEASE", 242, 244], ["MS", "PROBLEM", 72, 74], ["EPIDEMIOLOGYFamily studies", "TEST", 169, 195], ["genetic factors", "PROBLEM", 212, 227], ["MS", "PROBLEM", 242, 244], ["MS", "OBSERVATION", 72, 74], ["highest", "OBSERVATION_MODIFIER", 78, 85], ["upper", "ANATOMY_MODIFIER", 97, 102]]], ["The risk for developing MS within dizygotic twins is the same as for other siblings (3\u20135 per cent).", [["MS", "DISEASE", 24, 26], ["developing MS", "PROBLEM", 13, 26]]], ["However, the risk for monozygotic twins is greater than 30 per cent (O'Connor et al., 2002; Willer et al., 2003).", [["monozygotic twins", "PROBLEM", 22, 39]]], ["A greater than 10-fold increased risk of developing MS exists within individuals having certain human leukocyte antigens (HLA) genotypes (O'Connor et al., 2002; Sadovnick, 2002; Herrera and Ebers, 2003; Kenealy et al., 2003).", [["MS", "DISEASE", 52, 54], ["human leukocyte antigens", "GENE_OR_GENE_PRODUCT", 96, 120], ["human leukocyte antigens", "PROTEIN", 96, 120], ["HLA", "PROTEIN", 122, 125], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["A greater than 10-fold increased risk of developing MS", "PROBLEM", 0, 54], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["MS", "OBSERVATION", 52, 54]]], ["The major predisposing associated haplotype is HLA-DR2 in cellular typing nomenclature (DR15,DQ6 by serology and DRB50102-DQB115 and DRB1*17 alleles and MS has been seen in individuals of northern European and Mediterranean descent, the presence of these haplotypes does not preclude the development of MS (Sadovnick, 2002; Herrera and Ebers, 2003; Kenealy et al., 2003).", [["cellular", "ANATOMY", 58, 66], ["MS", "DISEASE", 153, 155], ["MS", "DISEASE", 303, 305], ["HLA-DR2", "GENE_OR_GENE_PRODUCT", 47, 54], ["cellular", "CELL", 58, 66], ["DQ6", "GENE_OR_GENE_PRODUCT", 93, 96], ["DRB50102-DQB115", "GENE_OR_GENE_PRODUCT", 113, 128], ["DRB1*17", "GENE_OR_GENE_PRODUCT", 133, 140], ["HLA-DR2", "DNA", 47, 54], ["DR15", "DNA", 88, 92], ["DQ6", "DNA", 93, 96], ["serology and DRB50102-DQB115 and DRB1*17 alleles", "DNA", 100, 148], ["serology", "TEST", 100, 108], ["DRB50102", "TEST", 113, 121], ["DRB1", "TEST", 133, 137], ["MS", "PROBLEM", 153, 155], ["these haplotypes", "PROBLEM", 249, 265]]], ["Genetic interactions may also occur between certain haplotypes and certain T cell receptors, immunoglobulins and tumor necrosis factors which may lead to an increased chance of developing MS (O'Connor et al., 2002; Alizadeh et al., 2003).EPIDEMIOLOGYNot only genetic but also one or more exogenous or environmental factors may influence the development of MS (O'Connor et al., 2002).", [["T cell", "ANATOMY", 75, 81], ["tumor", "ANATOMY", 113, 118], ["tumor", "DISEASE", 113, 118], ["necrosis", "DISEASE", 119, 127], ["MS", "DISEASE", 188, 190], ["MS", "DISEASE", 356, 358], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 75, 91], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 93, 108], ["tumor necrosis factors", "GENE_OR_GENE_PRODUCT", 113, 135], ["T cell receptors", "PROTEIN", 75, 91], ["immunoglobulins", "PROTEIN", 93, 108], ["tumor necrosis factors", "PROTEIN", 113, 135], ["Genetic interactions", "PROBLEM", 0, 20], ["certain haplotypes", "PROBLEM", 44, 62], ["certain T cell receptors", "PROBLEM", 67, 91], ["immunoglobulins", "PROBLEM", 93, 108], ["tumor necrosis factors", "PROBLEM", 113, 135], ["tumor necrosis", "OBSERVATION", 113, 127], ["increased", "OBSERVATION_MODIFIER", 157, 166]]], ["Although twin studies have provided strong evidence for genetic factors in the development of MS, the concordance rate for monozygotic twins has never been demonstrated to be greater than 40 per cent (Compston and Ebers, 1990; Sadovnick, 2002;Willer et al., 2003).", [["MS", "DISEASE", 94, 96], ["twin studies", "TEST", 9, 21], ["genetic factors", "PROBLEM", 56, 71], ["MS", "PROBLEM", 94, 96], ["the concordance rate", "TEST", 98, 118], ["monozygotic twins", "PROBLEM", 123, 140]]], ["Thus, at least 60 per cent of persons with an identical twin who has MS will not develop the disease.EPIDEMIOLOGYCertain foods, toxins, psychological stress, anesthesia, surgery and physical trauma have been implicated in the development of MS (O'Connor et al., 2002).", [["MS", "DISEASE", 69, 71], ["physical trauma", "DISEASE", 182, 197], ["MS", "DISEASE", 241, 243], ["persons", "ORGANISM", 30, 37], ["persons", "SPECIES", 30, 37], ["MS", "PROBLEM", 69, 71], ["anesthesia", "TREATMENT", 158, 168], ["surgery", "TREATMENT", 170, 177]]], ["However, no direct causal relationships have been proven to date.", [["no", "UNCERTAINTY", 9, 11]]], ["Overall, it is believed that both genetic and environmental factors are responsible for the subsequent development of MS within a susceptible individual (O'Connor et al., 2002).", [["MS", "DISEASE", 118, 120], ["MS", "PROBLEM", 118, 120]]], ["The resulting disability that results from MS leads to a major burden not only to the affected individual but also to the health care system and society (Whetten-Goldstein et al., 1998).PATHOPHYSIOLOGYLoss of myelin due to inflammation with limited subsequent remyelination are the two cardinal features of MS (Noseworthy et al., 2000).", [["myelin", "ANATOMY", 209, 215], ["disability", "DISEASE", 14, 24], ["MS", "DISEASE", 43, 45], ["inflammation", "DISEASE", 223, 235], ["MS", "DISEASE", 307, 309], ["myelin", "GENE_OR_GENE_PRODUCT", 209, 215], ["The resulting disability", "PROBLEM", 0, 24], ["myelin", "PROBLEM", 209, 215], ["inflammation", "PROBLEM", 223, 235], ["limited subsequent remyelination", "PROBLEM", 241, 273], ["myelin", "OBSERVATION", 209, 215], ["due to", "UNCERTAINTY", 216, 222], ["inflammation", "OBSERVATION", 223, 235], ["remyelination", "OBSERVATION", 260, 273]]], ["Breakdown of the blood\u2013brain barrier is typically observed with early inflammatory changes (Smith et al., 1993).", [["blood\u2013brain barrier", "ANATOMY", 17, 36], ["blood\u2013brain barrier", "TISSUE", 17, 36], ["Breakdown of the blood\u2013brain barrier", "PROBLEM", 0, 36], ["early inflammatory changes", "PROBLEM", 64, 90], ["early", "OBSERVATION_MODIFIER", 64, 69], ["inflammatory", "OBSERVATION", 70, 82]]], ["Immunocytochemical studies of active MS lesions have shown damage to vascular walls with intramural deposition of complement on smooth muscle components as well as protein-rich leakage (Noseworthy et al., 2000).", [["MS lesions", "ANATOMY", 37, 47], ["vascular walls", "ANATOMY", 69, 83], ["intramural", "ANATOMY", 89, 99], ["smooth muscle components", "ANATOMY", 128, 152], ["MS lesions", "CANCER", 37, 47], ["vascular walls", "MULTI-TISSUE_STRUCTURE", 69, 83], ["intramural", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 99], ["smooth muscle", "TISSUE", 128, 141], ["Immunocytochemical studies", "TEST", 0, 26], ["active MS lesions", "PROBLEM", 30, 47], ["damage to vascular walls", "PROBLEM", 59, 83], ["intramural deposition of complement on smooth muscle components", "PROBLEM", 89, 152], ["protein-rich leakage", "PROBLEM", 164, 184], ["active", "OBSERVATION_MODIFIER", 30, 36], ["MS", "OBSERVATION_MODIFIER", 37, 39], ["lesions", "OBSERVATION", 40, 47], ["damage", "OBSERVATION", 59, 65], ["vascular", "ANATOMY", 69, 77], ["walls", "ANATOMY_MODIFIER", 78, 83], ["intramural", "OBSERVATION_MODIFIER", 89, 99], ["deposition", "OBSERVATION", 100, 110], ["smooth muscle", "ANATOMY", 128, 141], ["rich", "OBSERVATION_MODIFIER", 172, 176], ["leakage", "OBSERVATION_MODIFIER", 177, 184]]], ["These abnormalities can occur within hours to days of an acute attack and slowly resolve over subsequent weeks to months (Poser, 1986).PATHOPHYSIOLOGYTypical pathological findings seen in MS are plaques containing inflammatory cells scattered throughout the affected parenchyma and arranged in cuffs around blood vessels (Figure 45.1).", [["plaques", "ANATOMY", 195, 202], ["inflammatory cells", "ANATOMY", 214, 232], ["parenchyma", "ANATOMY", 267, 277], ["cuffs", "ANATOMY", 294, 299], ["blood vessels", "ANATOMY", 307, 320], ["MS", "DISEASE", 188, 190], ["plaques", "DISEASE", 195, 202], ["inflammatory cells", "CELL", 214, 232], ["parenchyma", "TISSUE", 267, 277], ["cuffs", "TISSUE", 294, 299], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 307, 320], ["inflammatory cells", "CELL_TYPE", 214, 232], ["These abnormalities", "PROBLEM", 0, 19], ["an acute attack", "PROBLEM", 54, 69], ["PATHOPHYSIOLOGYTypical pathological findings", "PROBLEM", 135, 179], ["plaques", "PROBLEM", 195, 202], ["inflammatory cells", "PROBLEM", 214, 232], ["abnormalities", "OBSERVATION", 6, 19], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["attack", "OBSERVATION", 63, 69], ["plaques", "OBSERVATION", 195, 202], ["inflammatory cells", "OBSERVATION", 214, 232], ["scattered", "OBSERVATION_MODIFIER", 233, 242], ["affected", "OBSERVATION_MODIFIER", 258, 266], ["parenchyma", "ANATOMY_MODIFIER", 267, 277], ["cuffs", "OBSERVATION_MODIFIER", 294, 299], ["blood vessels", "ANATOMY", 307, 320]]], ["Inflammatory cells that are stimulated during an acute flare include macrophages, lymphocytes, large mononuclear cells and plasma cells (Prineas and Wright, 1978; Tourbah et al., 1993).", [["Inflammatory cells", "ANATOMY", 0, 18], ["macrophages", "ANATOMY", 69, 80], ["lymphocytes", "ANATOMY", 82, 93], ["mononuclear cells", "ANATOMY", 101, 118], ["plasma cells", "ANATOMY", 123, 135], ["Inflammatory cells", "CELL", 0, 18], ["macrophages", "CELL", 69, 80], ["lymphocytes", "CELL", 82, 93], ["large mononuclear cells", "CELL", 95, 118], ["plasma cells", "CELL", 123, 135], ["Prineas", "CELL", 137, 144], ["Inflammatory cells", "CELL_TYPE", 0, 18], ["macrophages", "CELL_TYPE", 69, 80], ["lymphocytes", "CELL_TYPE", 82, 93], ["large mononuclear cells", "CELL_TYPE", 95, 118], ["plasma cells", "CELL_TYPE", 123, 135], ["Inflammatory cells", "PROBLEM", 0, 18], ["an acute flare", "PROBLEM", 46, 60], ["macrophages", "PROBLEM", 69, 80], ["lymphocytes", "TEST", 82, 93], ["large mononuclear cells", "PROBLEM", 95, 118], ["plasma cells", "TEST", 123, 135], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["flare", "OBSERVATION", 55, 60], ["macrophages", "OBSERVATION", 69, 80], ["lymphocytes", "ANATOMY", 82, 93], ["large", "OBSERVATION_MODIFIER", 95, 100], ["mononuclear cells", "OBSERVATION", 101, 118], ["plasma cells", "OBSERVATION", 123, 135]]], ["In MS macrophages are immunologically active and can stimulate T cells leading to the subsequent production of large quantities of cytokines and inflammatory mediators (Hafler and Weiner, 1995; Hohlfeld et al., 1995; Martin and McFarland, 1995; O'Connor et al., 2000).", [["MS macrophages", "ANATOMY", 3, 17], ["T cells", "ANATOMY", 63, 70], ["MS macrophages", "CELL", 3, 17], ["T cells", "CELL", 63, 70], ["MS macrophages", "CELL_TYPE", 3, 17], ["T cells", "CELL_TYPE", 63, 70], ["cytokines", "PROTEIN", 131, 140], ["inflammatory mediators", "PROTEIN", 145, 167], ["macrophages", "OBSERVATION", 6, 17], ["large", "OBSERVATION_MODIFIER", 111, 116]]], ["These cytokines can be either pro-or anti-inflammatory in nature (Hafler and Weiner, 1995) with a T cell either stimulatory or inhibitory depending on surrounding environment factors (Hafler and Weiner, 1995; McFarland, 1995; Hohlfeld, 1997).PATHOPHYSIOLOGYAxonal loss has also shown to be a key factor in the pathogenesis of MS and is responsible for part of the irreversible clinical impairment and disability (O'Connor et al., 2002).", [["T cell", "ANATOMY", 98, 104], ["PATHOPHYSIOLOGYAxonal loss", "DISEASE", 242, 268], ["MS", "DISEASE", 326, 328], ["disability", "DISEASE", 401, 411], ["T cell", "CELL", 98, 104], ["cytokines", "PROTEIN", 6, 15], ["a T cell either stimulatory", "TREATMENT", 96, 123], ["PATHOPHYSIOLOGYAxonal loss", "PROBLEM", 242, 268], ["MS", "PROBLEM", 326, 328], ["the irreversible clinical impairment", "PROBLEM", 360, 396], ["loss", "OBSERVATION", 264, 268], ["responsible for", "UNCERTAINTY", 336, 351], ["irreversible", "OBSERVATION_MODIFIER", 364, 376]]], ["Axonal loss could stem from:1direct autoimmune attack against axons2a \u2018bystander injury\u2019 due to exposure of axons to immune attack following demyelination3degeneration of axons as a result of chronic demyelination4primary degeneration of axons, stimulating a secondary inflammatory response (Trapp et al., 1999; Lassmann, 2003).", [["Axonal", "ANATOMY", 0, 6], ["axons", "ANATOMY", 108, 113], ["axons", "ANATOMY", 171, 176], ["axons", "ANATOMY", 238, 243], ["Axonal loss", "DISEASE", 0, 11], ["Axonal", "MULTI-TISSUE_STRUCTURE", 0, 6], ["axons", "MULTI-TISSUE_STRUCTURE", 108, 113], ["axons", "MULTI-TISSUE_STRUCTURE", 171, 176], ["axons", "MULTI-TISSUE_STRUCTURE", 238, 243], ["Axonal loss", "PROBLEM", 0, 11], ["1direct autoimmune attack", "PROBLEM", 28, 53], ["bystander injury", "PROBLEM", 71, 87], ["immune attack", "PROBLEM", 117, 130], ["demyelination3degeneration of axons", "PROBLEM", 141, 176], ["chronic demyelination4primary degeneration of axons", "PROBLEM", 192, 243], ["a secondary inflammatory response", "PROBLEM", 257, 290], ["loss", "OBSERVATION", 7, 11], ["chronic", "OBSERVATION_MODIFIER", 192, 199], ["degeneration", "OBSERVATION", 222, 234], ["axons", "ANATOMY", 238, 243], ["secondary", "OBSERVATION_MODIFIER", 259, 268], ["inflammatory", "OBSERVATION_MODIFIER", 269, 281]]]], "PMC7139919": [], "cfd73d8fa874193e915881816557b665be987139": [["The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic has resulted in more than 60,000 deaths in the United States as of April 30, 2020.", [["Acute Respiratory Syndrome", "DISEASE", 11, 37], ["SARS-CoV-2)", "CHEMICAL", 53, 64], ["deaths", "DISEASE", 107, 113], ["SARS-CoV-2", "ORGANISM", 53, 63], ["Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2", "SPECIES", 4, 63], ["The Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 0, 49], ["CoV", "TEST", 58, 61], ["pandemic", "PROBLEM", 65, 73], ["Severe", "OBSERVATION_MODIFIER", 4, 10], ["Acute", "OBSERVATION_MODIFIER", 11, 16], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 17, 49]]], ["1 Although patients with liver disease have been deemed at increased risk for serious illness by the Centers for Disease Control and Prevention, 2 little is known about the natural history of SARS-CoV-2 in liver disease.", [["liver", "ANATOMY", 25, 30], ["liver", "ANATOMY", 206, 211], ["liver disease", "DISEASE", 25, 38], ["SARS", "DISEASE", 192, 196], ["liver disease", "DISEASE", 206, 219], ["patients", "ORGANISM", 11, 19], ["liver", "ORGAN", 25, 30], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 192, 202], ["liver", "ORGAN", 206, 211], ["patients", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 192, 200], ["liver disease", "PROBLEM", 25, 38], ["serious illness", "PROBLEM", 78, 93], ["Disease Control", "TREATMENT", 113, 128], ["SARS", "PROBLEM", 192, 196], ["liver disease", "PROBLEM", 206, 219], ["liver", "ANATOMY", 25, 30], ["disease", "OBSERVATION", 31, 38], ["serious", "OBSERVATION_MODIFIER", 78, 85], ["illness", "OBSERVATION", 86, 93], ["liver", "ANATOMY", 206, 211], ["disease", "OBSERVATION", 212, 219]]], ["Patients with advanced liver disease may be at increased risk because of immune dysfunction, frequent hospitalization, high rates of comorbidities (hypertension, diabetes, obesity), and decreased access to antiviral therapies that are potentially hepatotoxic (e.g., remdesivir, interleukin-6 pathway antagonists).", [["liver", "ANATOMY", 23, 28], ["liver disease", "DISEASE", 23, 36], ["immune dysfunction", "DISEASE", 73, 91], ["hypertension", "DISEASE", 148, 160], ["diabetes", "DISEASE", 162, 170], ["obesity", "DISEASE", 172, 179], ["hepatotoxic", "DISEASE", 247, 258], ["remdesivir", "CHEMICAL", 266, 276], ["remdesivir", "CHEMICAL", 266, 276], ["Patients", "ORGANISM", 0, 8], ["liver", "ORGAN", 23, 28], ["remdesivir", "SIMPLE_CHEMICAL", 266, 276], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 278, 291], ["Patients", "SPECIES", 0, 8], ["advanced liver disease", "PROBLEM", 14, 36], ["immune dysfunction", "PROBLEM", 73, 91], ["high rates of comorbidities", "PROBLEM", 119, 146], ["hypertension", "PROBLEM", 148, 160], ["diabetes", "PROBLEM", 162, 170], ["obesity", "PROBLEM", 172, 179], ["antiviral therapies", "TREATMENT", 206, 225], ["hepatotoxic", "PROBLEM", 247, 258], ["remdesivir", "TREATMENT", 266, 276], ["interleukin-6 pathway antagonists", "TREATMENT", 278, 311], ["advanced", "OBSERVATION_MODIFIER", 14, 22], ["liver", "ANATOMY", 23, 28], ["disease", "OBSERVATION", 29, 36], ["immune dysfunction", "OBSERVATION", 73, 91], ["hypertension", "OBSERVATION", 148, 160], ["potentially", "UNCERTAINTY", 235, 246], ["hepatotoxic", "OBSERVATION_MODIFIER", 247, 258]]], ["In the United States, the prevalence rate of liver disease is 2.3% in patients with SARS-CoV-2, 3 and international registries and population-based data suggest a high mortality in cirrhosis.", [["liver", "ANATOMY", 45, 50], ["liver disease", "DISEASE", 45, 58], ["SARS", "DISEASE", 84, 88], ["cirrhosis", "DISEASE", 181, 190], ["liver", "ORGAN", 45, 50], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["liver disease", "PROBLEM", 45, 58], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92], ["a high mortality in cirrhosis", "PROBLEM", 161, 190], ["liver", "ANATOMY", 45, 50], ["disease", "OBSERVATION", 51, 58], ["high", "OBSERVATION_MODIFIER", 163, 167], ["cirrhosis", "OBSERVATION", 181, 190]]], ["4, 5 However, the true prevalence and impact of SARS-CoV-2 on patients with liver disease remains unknown.", [["liver", "ANATOMY", 76, 81], ["SARS", "DISEASE", 48, 52], ["liver disease", "DISEASE", 76, 89], ["SARS-CoV-2", "ORGANISM", 48, 58], ["patients", "ORGANISM", 62, 70], ["liver", "ORGAN", 76, 81], ["patients", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "TEST", 48, 52], ["liver disease", "PROBLEM", 76, 89], ["liver", "ANATOMY", 76, 81], ["disease", "OBSERVATION", 82, 89]]]], "PMC3771849": [["IntroductionHypodermic needles are used for most biotherapeutic and vaccine injections,1 providing a low-cost, rapid, and direct way to deliver almost any type of molecule into the body.", [["body", "ANATOMY", 181, 185], ["body", "ORGANISM_SUBDIVISION", 181, 185], ["IntroductionHypodermic needles", "TREATMENT", 0, 30], ["biotherapeutic and vaccine injections", "TREATMENT", 49, 86], ["Hypodermic needles", "OBSERVATION", 12, 30], ["body", "ANATOMY", 181, 185]]], ["However, hypodermic needles are utilized primarily in the clinic or at home by patients who have received special training, and safe needle disposal2 and other issues such as transportation are problems.3 Conventional transdermal drug delivery offers many important advantages, such as accessibility, safety, painless drug administration, potential for self-administration, and avoidance of enzymatic degradation in the gastrointestinal tract or liver, but shows low bioavailability and poor permeability of drugs because of the physical barrier of the stratum corneum.4,5 For parenteral controlled-release formulations, in situ-forming implants are also attractive alternatives to preformed implants and microparticles, avoiding the use of large needles or microsurgery and with relatively low cost of manufacture.", [["gastrointestinal tract", "ANATOMY", 420, 442], ["liver", "ANATOMY", 446, 451], ["stratum corneum", "ANATOMY", 553, 568], ["patients", "ORGANISM", 79, 87], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 420, 442], ["liver", "ORGAN", 446, 451], ["stratum corneum", "TISSUE", 553, 568], ["patients", "SPECIES", 79, 87], ["hypodermic needles", "TREATMENT", 9, 27], ["special training", "TREATMENT", 106, 122], ["safe needle disposal2", "TREATMENT", 128, 149], ["Conventional transdermal drug delivery", "TREATMENT", 205, 243], ["painless drug administration", "TREATMENT", 309, 337], ["self-administration", "TREATMENT", 353, 372], ["enzymatic degradation in the gastrointestinal tract", "PROBLEM", 391, 442], ["low bioavailability", "PROBLEM", 463, 482], ["poor permeability of drugs", "PROBLEM", 487, 513], ["parenteral controlled-release formulations", "TREATMENT", 577, 619], ["situ-forming implants", "TREATMENT", 624, 645], ["preformed implants and microparticles", "TREATMENT", 682, 719], ["large needles", "TREATMENT", 741, 754], ["microsurgery", "TREATMENT", 758, 770], ["hypodermic needles", "OBSERVATION", 9, 27], ["gastrointestinal tract", "ANATOMY", 420, 442], ["liver", "ANATOMY", 446, 451], ["low bioavailability", "OBSERVATION_MODIFIER", 463, 482], ["stratum corneum", "ANATOMY", 553, 568], ["large", "OBSERVATION_MODIFIER", 741, 746], ["needles", "OBSERVATION", 747, 754]]], ["Such a system stays in a solid state before administration and becomes a hydrogel in situ after injection into the body.", [["body", "ANATOMY", 115, 119], ["body", "ORGANISM_SUBDIVISION", 115, 119], ["a hydrogel in situ", "TREATMENT", 71, 89], ["body", "ANATOMY", 115, 119]]], ["However, key issues remain to be solved, including variability of the implant shape and structure, avoidance of burst release during implant formation, and toxicity issues, thus these are far from practical use.6 Recently, Peng et al combined nanoparticle and thermosensitive hydrogel technologies in an appropriate manner, which would be a promising system for longer sustained and controlled drug delivery.7 However, compared to microneedle technologies, the promising system might have lower patient compliance and transportation convenience.", [["toxicity", "DISEASE", 156, 164], ["patient", "ORGANISM", 495, 502], ["patient", "SPECIES", 495, 502], ["variability of the implant shape", "PROBLEM", 51, 83], ["burst release during implant formation", "PROBLEM", 112, 150], ["toxicity issues", "PROBLEM", 156, 171], ["Peng et al combined nanoparticle", "TREATMENT", 223, 255], ["thermosensitive hydrogel technologies", "TREATMENT", 260, 297], ["drug delivery", "TREATMENT", 394, 407], ["microneedle technologies", "TEST", 431, 455], ["implant shape", "OBSERVATION", 70, 83]]], ["Deadman et al reported more recently that an in situ-forming drug depot, Eligard, was approved by the US Food and Drug Administration.", [["Eligard", "CHEMICAL", 73, 80], ["Eligard", "SIMPLE_CHEMICAL", 73, 80], ["Drug Administration", "TREATMENT", 114, 133]]], ["Upon administration, the water-miscible organic solvent dissipates into the surrounding tissue, which leads to polymer precipitation into a depot at the site of injection, entrapping the drug.", [["tissue", "ANATOMY", 88, 94], ["tissue", "TISSUE", 88, 94], ["administration", "TREATMENT", 5, 19], ["the water-miscible organic solvent", "TREATMENT", 21, 55], ["surrounding tissue", "ANATOMY", 76, 94], ["polymer precipitation", "OBSERVATION", 111, 132]]], ["The obvious disadvantages are the fact that an organic solvent is administered (which can lead to toxicity) and the variable shape and size of the implant formed in vivo, which leads to variable rates of drug release.8IntroductionMicroneedle technologies, which were first conceptualized for drug delivery many decades ago, overcome the shortages and preserve the advantages of hypodermic needles and conventional transdermal drug-delivery systems to some extent.", [["toxicity", "DISEASE", 98, 106], ["an organic solvent", "TREATMENT", 44, 62], ["toxicity", "PROBLEM", 98, 106], ["the variable shape", "PROBLEM", 112, 130], ["the implant", "TREATMENT", 143, 154], ["IntroductionMicroneedle technologies", "TREATMENT", 218, 254], ["drug delivery", "TREATMENT", 292, 305], ["hypodermic needles", "TREATMENT", 378, 396], ["conventional transdermal drug-delivery systems", "TREATMENT", 401, 447], ["variable", "OBSERVATION_MODIFIER", 116, 124], ["shape", "OBSERVATION_MODIFIER", 125, 130], ["size", "OBSERVATION_MODIFIER", 135, 139], ["implant", "OBSERVATION", 147, 154], ["hypodermic needles", "OBSERVATION", 378, 396]]], ["They are also superior to in situ-forming implants and in situ-forming drug depot in some fields.", [["situ-forming implants", "TREATMENT", 29, 50], ["implants", "OBSERVATION", 42, 50], ["drug depot", "OBSERVATION", 71, 81]]], ["Microneedles are needle-like structures with diameters in the size order of microns and lengths up to 900 \u03bcm.9 These structures are used to pierce the upper layer of the skin to enhance transdermal drug delivery by enabling the transport of a host of molecules that cannot be delivered across the skin by passive diffusion alone.10 There is no size limit for delivery of macromolecules through these microchannels, as the size of these microchannels is in microns and the maximum dimension of typical macromolecules administered into the body are in nanometers,11 thus microneedles can be used to deliver such macromolecules as insulin, growth hormones, immunobiologicals, proteins, and peptides.12IntroductionMicroneedle technologies can be divided into several categories: solid microneedles for skin pretreatment to increase skin permeability, microneedles coated with drugs, polymer microneedles that encapsulate drugs and fully or partially dissolve in the skin, and hollow microneedles for drug infusion into the skin.13,14IntroductionMicroneedles are mostly applied for the transdermal delivery of drugs and vaccines that may require long exposure, among which the dissolving and biodegradable microneedle technologies are most commonly seen.", [["skin", "ANATOMY", 170, 174], ["skin", "ANATOMY", 297, 301], ["body", "ANATOMY", 538, 542], ["skin", "ANATOMY", 798, 802], ["skin", "ANATOMY", 828, 832], ["skin", "ANATOMY", 962, 966], ["skin", "ANATOMY", 1019, 1023], ["skin", "ORGAN", 170, 174], ["skin", "ORGAN", 297, 301], ["body", "ORGANISM_SUBDIVISION", 538, 542], ["insulin", "GENE_OR_GENE_PRODUCT", 628, 635], ["immunobiologicals", "SIMPLE_CHEMICAL", 654, 671], ["skin", "ORGAN", 798, 802], ["skin", "ORGAN", 828, 832], ["skin", "ORGAN", 962, 966], ["skin", "ORGAN", 1019, 1023], ["insulin", "PROTEIN", 628, 635], ["needle", "TEST", 17, 23], ["lengths", "TEST", 88, 95], ["transdermal drug delivery", "TREATMENT", 186, 211], ["a host of molecules", "TREATMENT", 241, 260], ["delivery of macromolecules through these microchannels", "TREATMENT", 359, 413], ["typical macromolecules", "TREATMENT", 493, 515], ["microneedles", "TREATMENT", 569, 581], ["such macromolecules", "TREATMENT", 605, 624], ["insulin", "TREATMENT", 628, 635], ["immunobiologicals", "TEST", 654, 671], ["peptides", "TEST", 687, 695], ["IntroductionMicroneedle technologies", "TREATMENT", 698, 734], ["solid microneedles", "TREATMENT", 775, 793], ["skin pretreatment", "TREATMENT", 798, 815], ["skin permeability, microneedles coated with drugs", "TREATMENT", 828, 877], ["polymer microneedles", "TREATMENT", 879, 899], ["drugs", "TREATMENT", 917, 922], ["hollow microneedles", "TREATMENT", 972, 991], ["drug infusion", "TREATMENT", 996, 1009], ["IntroductionMicroneedles", "TREATMENT", 1029, 1053], ["the transdermal delivery of drugs", "TREATMENT", 1077, 1110], ["vaccines", "TREATMENT", 1115, 1123], ["long exposure", "TREATMENT", 1141, 1154], ["the dissolving and biodegradable microneedle technologies", "TREATMENT", 1168, 1225], ["diameters", "OBSERVATION_MODIFIER", 45, 54], ["size", "OBSERVATION_MODIFIER", 62, 66], ["upper", "ANATOMY_MODIFIER", 151, 156], ["layer", "ANATOMY_MODIFIER", 157, 162], ["skin", "ANATOMY", 170, 174], ["skin", "ANATOMY", 297, 301], ["no", "UNCERTAINTY", 341, 343], ["size", "OBSERVATION_MODIFIER", 344, 348], ["size", "OBSERVATION_MODIFIER", 422, 426], ["microchannels", "OBSERVATION_MODIFIER", 436, 449], ["microns", "OBSERVATION_MODIFIER", 456, 463], ["maximum", "OBSERVATION_MODIFIER", 472, 479], ["dimension", "OBSERVATION_MODIFIER", 480, 489], ["typical", "OBSERVATION_MODIFIER", 493, 500], ["macromolecules", "OBSERVATION", 501, 515], ["body", "ANATOMY", 538, 542], ["skin", "ANATOMY", 798, 802], ["skin", "ANATOMY", 828, 832], ["skin", "ANATOMY", 962, 966], ["skin", "ANATOMY", 1019, 1023]]], ["Compared to bolus delivery, the sustained delivery of drug and vaccine is more complicated and is a trend in microneedle technology, thus this article reviews this body of work.Skin microanatomy and the geometry of microneedles ::: Drug and vaccine delivery methods via the skinThe stratum corneum is 15\u201320 \u03bcm thick and is indispensable as a barrier.", [["Skin", "ANATOMY", 177, 181], ["skin", "ANATOMY", 274, 278], ["stratum corneum", "ANATOMY", 282, 297], ["Skin", "ORGAN", 177, 181], ["skin", "ORGAN", 274, 278], ["stratum corneum", "TISSUE", 282, 297], ["bolus delivery", "TREATMENT", 12, 26], ["drug and vaccine", "TREATMENT", 54, 70], ["Drug and vaccine delivery methods", "TREATMENT", 232, 265], ["thick", "PROBLEM", 310, 315], ["microanatomy", "OBSERVATION", 182, 194], ["skin", "ANATOMY", 274, 278], ["stratum", "ANATOMY_MODIFIER", 282, 289], ["corneum", "ANATOMY", 290, 297]]], ["The viable epidermis is located below the stratum corneum, and has a thickness of 130\u2013180 \u03bcm.", [["epidermis", "ANATOMY", 11, 20], ["stratum corneum", "ANATOMY", 42, 57], ["epidermis", "ORGAN", 11, 20], ["stratum corneum", "TISSUE", 42, 57], ["a thickness", "TEST", 67, 78], ["viable", "OBSERVATION_MODIFIER", 4, 10], ["epidermis", "OBSERVATION", 11, 20], ["stratum corneum", "ANATOMY", 42, 57], ["thickness", "OBSERVATION_MODIFIER", 69, 78]]], ["Below the epidermis lies the dermis, which is about 2,000 \u03bcm thick and contains nerves, blood vessels, nociceptors, lymph vessels, hair follicles, and sweat glands (Figure 1).15 The epidermal or epithelial layer is a covering carried in the superficial dermis or superficial lamina in the superficial plexus.", [["epidermis", "ANATOMY", 10, 19], ["dermis", "ANATOMY", 29, 35], ["nerves", "ANATOMY", 80, 86], ["blood vessels", "ANATOMY", 88, 101], ["nociceptors", "ANATOMY", 103, 114], ["lymph vessels", "ANATOMY", 116, 129], ["hair follicles", "ANATOMY", 131, 145], ["sweat glands", "ANATOMY", 151, 163], ["epidermal", "ANATOMY", 182, 191], ["epithelial layer", "ANATOMY", 195, 211], ["superficial dermis", "ANATOMY", 241, 259], ["superficial lamina", "ANATOMY", 263, 281], ["superficial plexus", "ANATOMY", 289, 307], ["epidermis", "TISSUE", 10, 19], ["dermis", "TISSUE", 29, 35], ["nerves", "TISSUE", 80, 86], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 88, 101], ["nociceptors", "TISSUE", 103, 114], ["lymph vessels", "MULTI-TISSUE_STRUCTURE", 116, 129], ["hair follicles", "MULTI-TISSUE_STRUCTURE", 131, 145], ["sweat glands", "ORGAN", 151, 163], ["epidermal", "TISSUE", 182, 191], ["epithelial layer", "TISSUE", 195, 211], ["superficial dermis", "TISSUE", 241, 259], ["superficial lamina", "TISSUE", 263, 281], ["superficial plexus", "MULTI-TISSUE_STRUCTURE", 289, 307], ["nociceptors", "TEST", 103, 114], ["epidermis", "ANATOMY", 10, 19], ["dermis", "ANATOMY", 29, 35], ["nerves", "ANATOMY", 80, 86], ["blood vessels", "ANATOMY", 88, 101], ["nociceptors", "ANATOMY", 103, 114], ["lymph vessels", "OBSERVATION", 116, 129], ["hair follicles", "OBSERVATION", 131, 145], ["sweat glands", "ANATOMY", 151, 163], ["epidermal", "OBSERVATION_MODIFIER", 182, 191], ["epithelial", "ANATOMY_MODIFIER", 195, 205], ["layer", "OBSERVATION_MODIFIER", 206, 211], ["superficial", "ANATOMY_MODIFIER", 241, 252], ["dermis", "ANATOMY", 253, 259], ["superficial", "ANATOMY_MODIFIER", 263, 274], ["lamina", "ANATOMY_MODIFIER", 275, 281], ["superficial plexus", "ANATOMY", 289, 307]]], ["In the case of skin as a model, the plexus is the intradermal plexus.", [["skin", "ANATOMY", 15, 19], ["plexus", "ANATOMY", 36, 42], ["intradermal plexus", "ANATOMY", 50, 68], ["skin", "ORGAN", 15, 19], ["plexus", "MULTI-TISSUE_STRUCTURE", 36, 42], ["intradermal plexus", "MULTI-TISSUE_STRUCTURE", 50, 68], ["skin", "ANATOMY", 15, 19], ["plexus", "ANATOMY", 36, 42], ["intradermal plexus", "ANATOMY", 50, 68]]], ["There are some lymphatic vessels in that layer.", [["lymphatic vessels", "ANATOMY", 15, 32], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 15, 32], ["some lymphatic vessels in that layer", "PROBLEM", 10, 46], ["some", "OBSERVATION_MODIFIER", 10, 14], ["lymphatic vessels", "OBSERVATION", 15, 32], ["layer", "OBSERVATION_MODIFIER", 41, 46]]], ["In the deep dermal layer or deep lamina, the deep plexus is carried.", [["dermal layer", "ANATOMY", 12, 24], ["deep lamina", "ANATOMY", 28, 39], ["deep plexus", "ANATOMY", 45, 56], ["dermal layer", "TISSUE", 12, 24], ["lamina", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 39], ["deep plexus", "MULTI-TISSUE_STRUCTURE", 45, 56], ["deep", "ANATOMY_MODIFIER", 7, 11], ["dermal", "ANATOMY", 12, 18], ["layer", "ANATOMY_MODIFIER", 19, 24], ["deep", "ANATOMY_MODIFIER", 28, 32], ["lamina", "ANATOMY_MODIFIER", 33, 39], ["deep plexus", "ANATOMY", 45, 56]]], ["In the case of skin, this is the subdermal plexus.", [["skin", "ANATOMY", 15, 19], ["subdermal plexus", "ANATOMY", 33, 49], ["skin", "ORGAN", 15, 19], ["subdermal plexus", "MULTI-TISSUE_STRUCTURE", 33, 49], ["skin", "ANATOMY", 15, 19], ["subdermal plexus", "ANATOMY", 33, 49]]], ["In that layer, there are most of the lymphatic vessels, and the collagen content of that layer is much greater than in the superficial layer.16 It has long been recognized as a highly immune reactive tissue containing an abundance of antigen-presenting cells and immunocompetent cells, especially within the epidermal and dermal skin layers.17,18Skin microanatomy and the geometry of microneedles ::: Drug and vaccine delivery methods via the skinSkin microanatomy largely determines the geometry of microneedles.", [["lymphatic vessels", "ANATOMY", 37, 54], ["superficial layer", "ANATOMY", 123, 140], ["tissue", "ANATOMY", 200, 206], ["antigen-presenting cells", "ANATOMY", 234, 258], ["cells", "ANATOMY", 279, 284], ["epidermal", "ANATOMY", 308, 317], ["dermal skin layers", "ANATOMY", 322, 340], ["Skin", "ANATOMY", 346, 350], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 37, 54], ["collagen", "GENE_OR_GENE_PRODUCT", 64, 72], ["superficial layer", "TISSUE", 123, 140], ["tissue", "TISSUE", 200, 206], ["cells", "CELL", 253, 258], ["immunocompetent cells", "CELL", 263, 284], ["epidermal", "TISSUE", 308, 317], ["dermal skin layers", "TISSUE", 322, 340], ["Skin", "ORGAN", 346, 350], ["collagen", "PROTEIN", 64, 72], ["antigen-presenting cells", "CELL_TYPE", 234, 258], ["immunocompetent cells", "CELL_TYPE", 263, 284], ["a highly immune reactive tissue", "PROBLEM", 175, 206], ["presenting cells", "PROBLEM", 242, 258], ["immunocompetent cells", "PROBLEM", 263, 284], ["Drug and vaccine delivery methods", "TREATMENT", 401, 434], ["layer", "OBSERVATION_MODIFIER", 8, 13], ["lymphatic vessels", "ANATOMY", 37, 54], ["collagen", "OBSERVATION_MODIFIER", 64, 72], ["content", "OBSERVATION_MODIFIER", 73, 80], ["layer", "OBSERVATION_MODIFIER", 89, 94], ["much", "OBSERVATION_MODIFIER", 98, 102], ["greater", "OBSERVATION_MODIFIER", 103, 110], ["superficial", "ANATOMY_MODIFIER", 123, 134], ["layer", "ANATOMY_MODIFIER", 135, 140], ["highly immune", "OBSERVATION_MODIFIER", 177, 190], ["reactive tissue", "OBSERVATION", 191, 206], ["abundance", "OBSERVATION_MODIFIER", 221, 230], ["immunocompetent cells", "OBSERVATION", 263, 284], ["epidermal", "ANATOMY", 308, 317], ["dermal", "ANATOMY_MODIFIER", 322, 328], ["skin", "ANATOMY", 329, 333], ["layers", "ANATOMY_MODIFIER", 334, 340], ["Skin", "ANATOMY", 346, 350], ["microanatomy", "OBSERVATION", 351, 363]]], ["Yana et al proved that microneedle arrays with longer needles (>600 \u03bcm) were more effective in creating pathways across skin and enhancing drug flux, and microneedle arrays with lower needle densities (<2,000 needles/cm2) were more effective in enhancing drug flux if the microneedles had sufficient length (>600 \u03bcm).19 Noh et al20 measured skin irritation using microneedles of 500 \u03bcm depth, and concluded that there was little difference in the decrease of redness after microneedle application based on application time, but redness was generally maintained until 30 minutes and rapidly decreased between 30 minutes and 2 hours.", [["skin", "ANATOMY", 120, 124], ["skin", "ANATOMY", 341, 345], ["skin irritation", "DISEASE", 341, 356], ["redness", "DISEASE", 459, 466], ["skin", "ORGAN", 120, 124], ["skin", "ORGAN", 341, 345], ["microneedle arrays with longer needles", "TREATMENT", 23, 61], ["enhancing drug flux", "TREATMENT", 129, 148], ["microneedle arrays with lower needle densities", "TREATMENT", 154, 200], ["skin irritation", "PROBLEM", 341, 356], ["the decrease of redness", "PROBLEM", 443, 466], ["microneedle application", "TREATMENT", 473, 496], ["redness", "PROBLEM", 528, 535], ["skin", "ANATOMY", 120, 124], ["enhancing", "OBSERVATION_MODIFIER", 129, 138], ["drug flux", "OBSERVATION", 139, 148], ["skin", "ANATOMY", 341, 345], ["irritation", "OBSERVATION", 346, 356], ["little", "OBSERVATION_MODIFIER", 422, 428], ["difference", "OBSERVATION_MODIFIER", 429, 439], ["decrease", "OBSERVATION_MODIFIER", 447, 455], ["redness", "OBSERVATION", 459, 466], ["redness", "OBSERVATION", 528, 535]]], ["Gomaa et al21 found that when 600 \u03bcm-long microneedles were applied to the dermal side of skin, the transepidermal water-loss measurements remained at baseline levels.", [["dermal", "ANATOMY", 75, 81], ["skin", "ANATOMY", 90, 94], ["transepidermal", "ANATOMY", 100, 114], ["dermal side", "MULTI-TISSUE_STRUCTURE", 75, 86], ["skin", "ORGAN", 90, 94], ["600 \u03bcm-long microneedles", "TREATMENT", 30, 54], ["the transepidermal water-loss measurements", "TEST", 96, 138], ["skin", "ANATOMY", 90, 94]]], ["This is explainable by the fact that typically only 10%\u201330% of the needle length actually penetrates tissue.22 Gomaa et al21 also found that increasing microneedle density introduced complex effects.", [["tissue", "ANATOMY", 101, 107], ["tissue", "TISSUE", 101, 107], ["increasing microneedle density", "PROBLEM", 141, 171], ["increasing", "OBSERVATION_MODIFIER", 141, 151], ["microneedle", "OBSERVATION_MODIFIER", 152, 163], ["density", "OBSERVATION", 164, 171], ["complex", "OBSERVATION_MODIFIER", 183, 190]]], ["Firstly, more skin channels may have been created, and these inhibited the long-term, tissue contraction-mediated partial recovery of the barrier.", [["skin", "ANATOMY", 14, 18], ["tissue", "ANATOMY", 86, 92], ["skin", "ORGAN", 14, 18], ["tissue", "TISSUE", 86, 92], ["barrier", "TISSUE", 138, 145], ["more skin channels", "PROBLEM", 9, 27], ["the barrier", "TREATMENT", 134, 145], ["skin", "ANATOMY", 14, 18]]], ["However, there was also some evidence that at high microneedle densities, individual needles may no longer effectively breach the barrier due to a \u201cbed of nails\u201d effect.", [["nails", "ANATOMY", 155, 160], ["high microneedle densities", "PROBLEM", 46, 72], ["individual needles", "TREATMENT", 74, 92], ["high", "OBSERVATION_MODIFIER", 46, 50], ["microneedle", "OBSERVATION_MODIFIER", 51, 62], ["densities", "OBSERVATION", 63, 72], ["no longer", "UNCERTAINTY", 97, 106], ["nails", "OBSERVATION", 155, 160]]], ["Leaving the array embedded in the skin seemed to diminish the magnitude of the initial postinsertion drop in barrier function.", [["skin", "ANATOMY", 34, 38], ["barrier", "ANATOMY", 109, 116], ["skin", "ORGAN", 34, 38], ["barrier", "TISSUE", 109, 116], ["skin", "ANATOMY", 34, 38], ["barrier function", "OBSERVATION", 109, 125]]], ["Furthermore, Lee et al23 concluded that pyramidal microneedles were stronger than conical ones, probably due to their larger cross-sectional area at the same base width/diameter.Dissolving microneedles ::: Drug and vaccine delivery methods via the skinDissolving microneedles, mostly using different kinds of sugars as the matrix (Figure 2), usually release drugs or vaccines quickly in vivo,24 eg, Ito et al25 reported that insulin released from microneedles very quickly, and almost all of the formulated insulin was released within 1 hour when dextrin was used as matrix.", [["pyramidal", "ANATOMY", 40, 49], ["insulin", "CHEMICAL", 507, 514], ["dextrin", "CHEMICAL", 547, 554], ["sugars", "CHEMICAL", 309, 315], ["matrix", "CELLULAR_COMPONENT", 323, 329], ["insulin", "GENE_OR_GENE_PRODUCT", 425, 432], ["insulin", "GENE_OR_GENE_PRODUCT", 507, 514], ["dextrin", "SIMPLE_CHEMICAL", 547, 554], ["matrix", "CELLULAR_COMPONENT", 567, 573], ["insulin", "PROTEIN", 425, 432], ["insulin", "PROTEIN", 507, 514], ["pyramidal microneedles", "TREATMENT", 40, 62], ["Drug and vaccine delivery methods", "TREATMENT", 206, 239], ["the skinDissolving microneedles", "TREATMENT", 244, 275], ["vaccines", "TREATMENT", 367, 375], ["insulin", "TREATMENT", 425, 432], ["the formulated insulin", "TREATMENT", 492, 514], ["dextrin", "TREATMENT", 547, 554], ["probably due to", "UNCERTAINTY", 96, 111], ["larger", "OBSERVATION_MODIFIER", 118, 124], ["base", "ANATOMY_MODIFIER", 158, 162], ["width", "OBSERVATION_MODIFIER", 163, 168], ["diameter", "OBSERVATION_MODIFIER", 169, 177]]], ["Nevertheless, sustained release of drugs or vaccines is also required under some circumstances.", [["drugs", "TREATMENT", 35, 40], ["vaccines", "TREATMENT", 44, 52]]], ["Lee et al23 prepared microneedles with model drug encapsulated not within the microneedle tips but only in the backing layer, which served as a controlled-release reservoir that delivered molecules by a combination of swelling the backing with interstitial fluid drawn out of the skin and molecule diffusion into the skin via channels formed by dissolved microneedles.", [["interstitial fluid", "ANATOMY", 244, 262], ["skin", "ANATOMY", 280, 284], ["skin", "ANATOMY", 317, 321], ["skin", "ORGAN", 280, 284], ["skin", "ORGAN", 317, 321], ["Lee et al23 prepared microneedles", "TREATMENT", 0, 33], ["model drug", "TREATMENT", 39, 49], ["the microneedle tips", "TREATMENT", 74, 94], ["a controlled-release reservoir", "TREATMENT", 142, 172], ["swelling", "PROBLEM", 218, 226], ["interstitial fluid", "PROBLEM", 244, 262], ["swelling", "OBSERVATION", 218, 226], ["interstitial", "ANATOMY_MODIFIER", 244, 256], ["fluid", "OBSERVATION", 257, 262], ["skin", "ANATOMY", 280, 284], ["molecule diffusion", "OBSERVATION", 289, 307], ["skin", "ANATOMY", 317, 321], ["dissolved microneedles", "OBSERVATION", 345, 367]]], ["They revealed that sulforhodamine release from carboxymethyl cellulose microneedle patches exhibited an initial lag time of a few hours, followed by steady release for approximately 1 day.", [["sulforhodamine", "CHEMICAL", 19, 33], ["carboxymethyl cellulose", "CHEMICAL", 47, 70], ["sulforhodamine", "CHEMICAL", 19, 33], ["carboxymethyl", "CHEMICAL", 47, 60], ["sulforhodamine", "SIMPLE_CHEMICAL", 19, 33], ["carboxymethyl cellulose", "SIMPLE_CHEMICAL", 47, 70], ["sulforhodamine release", "TREATMENT", 19, 41], ["carboxymethyl cellulose microneedle patches", "TREATMENT", 47, 90]]], ["Similar behavior was seen for microneedle patches made of amylopectin, but with slower kinetics.", [["amylopectin", "CHEMICAL", 58, 69], ["amylopectin", "SIMPLE_CHEMICAL", 58, 69], ["microneedle patches", "TREATMENT", 30, 49], ["amylopectin", "TREATMENT", 58, 69], ["slower kinetics", "PROBLEM", 80, 95], ["slower kinetics", "OBSERVATION", 80, 95]]], ["Polymeric dissolving microneedles designed by Donnelly et al have been produced from Gantrez AN-139, and delivered 83% of the encapsulated theophylline into porcine skin within 24 hours.26Dissolving microneedles ::: Drug and vaccine delivery methods via the skinKumar et al27 characterized and used maltose microneedles to microporate full-thickness pig-ear skin to evaluate drug delivery of model small (calcein) and large (human growth hormone) molecules.", [["skin", "ANATOMY", 165, 169], ["ear skin", "ANATOMY", 354, 362], ["Gantrez AN-139", "CHEMICAL", 85, 99], ["theophylline", "CHEMICAL", 139, 151], ["calcein", "CHEMICAL", 405, 412], ["theophylline", "CHEMICAL", 139, 151], ["maltose", "CHEMICAL", 299, 306], ["calcein", "CHEMICAL", 405, 412], ["Gantrez AN-139", "CELL", 85, 99], ["theophylline", "SIMPLE_CHEMICAL", 139, 151], ["porcine", "ORGANISM", 157, 164], ["skin", "ORGAN", 165, 169], ["maltose", "SIMPLE_CHEMICAL", 299, 306], ["pig", "ORGANISM", 350, 353], ["ear", "ORGAN", 354, 357], ["skin", "ORGAN", 358, 362], ["calcein", "SIMPLE_CHEMICAL", 405, 412], ["human", "ORGANISM", 425, 430], ["porcine", "SPECIES", 157, 164], ["pig", "SPECIES", 350, 353], ["human", "SPECIES", 425, 430], ["Gantrez AN-139", "SPECIES", 85, 99], ["porcine", "SPECIES", 157, 164], ["pig", "SPECIES", 350, 353], ["human", "SPECIES", 425, 430], ["Polymeric dissolving microneedles", "TREATMENT", 0, 33], ["the encapsulated theophylline", "TREATMENT", 122, 151], ["Drug and vaccine delivery methods", "TREATMENT", 216, 249], ["the skinKumar et al27", "TREATMENT", 254, 275], ["maltose microneedles", "TREATMENT", 299, 319], ["microporate full-thickness pig-ear skin", "TREATMENT", 323, 362], ["drug delivery", "TREATMENT", 375, 388], ["model small (calcein)", "PROBLEM", 392, 413], ["large (human growth hormone) molecules", "PROBLEM", 418, 456], ["skin", "ANATOMY", 165, 169], ["ear", "ANATOMY", 354, 357], ["skin", "ANATOMY", 358, 362], ["small", "OBSERVATION_MODIFIER", 398, 403], ["large", "OBSERVATION_MODIFIER", 418, 423]]], ["It was found that modulated transdermal delivery of small as well as large molecules is possible upon microporation of the skin in combination with iontophoresis (ITP).", [["skin", "ANATOMY", 123, 127], ["ITP", "DISEASE", 163, 166], ["transdermal", "SIMPLE_CHEMICAL", 28, 39], ["skin", "ORGAN", 123, 127], ["modulated transdermal delivery", "TREATMENT", 18, 48], ["large molecules", "PROBLEM", 69, 84], ["iontophoresis (ITP", "TREATMENT", 148, 166], ["transdermal", "OBSERVATION_MODIFIER", 28, 39], ["small", "OBSERVATION_MODIFIER", 52, 57], ["large", "OBSERVATION_MODIFIER", 69, 74], ["molecules", "OBSERVATION", 75, 84], ["skin", "ANATOMY", 123, 127]]], ["The modulated ITP protocol resulted in peaks in flux with application of current and gradual decrease with termination of current, and current density and time could be used appropriately to program a desired drug-delivery profile.", [["ITP", "DISEASE", 14, 17], ["The modulated ITP protocol", "TREATMENT", 0, 26], ["a desired drug-delivery profile", "TREATMENT", 199, 230], ["ITP", "OBSERVATION", 14, 17], ["peaks", "OBSERVATION_MODIFIER", 39, 44], ["flux", "OBSERVATION_MODIFIER", 48, 52], ["gradual", "OBSERVATION_MODIFIER", 85, 92], ["decrease", "OBSERVATION_MODIFIER", 93, 101], ["density", "OBSERVATION", 143, 150]]], ["Garland et al28 studied the potential for ITP to be combined with polymeric microneedle devices that remain in contact with the skin during the course of drug delivery procedure for the first time.", [["skin", "ANATOMY", 128, 132], ["ITP", "DISEASE", 42, 45], ["skin", "ORGAN", 128, 132], ["ITP", "PROBLEM", 42, 45], ["polymeric microneedle devices", "TREATMENT", 66, 95], ["drug delivery procedure", "TREATMENT", 154, 177], ["skin", "ANATOMY", 128, 132]]], ["Furthermore, it has been shown that the application of an electric current enables the permeation of macromolecules from the entire microneedle-array matrix, and not just that which was contained within the microneedles alone.", [["matrix", "CELLULAR_COMPONENT", 150, 156], ["the permeation of macromolecules", "TREATMENT", 83, 115], ["the entire microneedle-array matrix", "TREATMENT", 121, 156]]], ["Thus the application of an electric current significantly increased the extent of macromolecular delivery from the poly(methyl vinyl ether maleic anhydride) microneedle array, which is also promising for the sustained delivery of drugs and vaccines.", [["poly(methyl vinyl ether maleic anhydride", "CHEMICAL", 115, 155], ["poly(methyl vinyl ether maleic anhydride)", "CHEMICAL", 115, 156], ["poly(methyl vinyl ether maleic anhydride", "SIMPLE_CHEMICAL", 115, 155], ["macromolecular delivery", "TREATMENT", 82, 105], ["the poly(methyl vinyl ether maleic anhydride) microneedle array", "TREATMENT", 111, 174], ["drugs", "TREATMENT", 230, 235], ["vaccines", "TREATMENT", 240, 248], ["extent", "OBSERVATION_MODIFIER", 72, 78], ["macromolecular delivery", "OBSERVATION", 82, 105]]], ["Wu et al29 reported a similar finding, wherein the transdermal permeation of high-molecular-weight compounds through microneedle-induced channels could be increased through the combination of ITP.", [["ITP", "DISEASE", 192, 195], ["transdermal", "SIMPLE_CHEMICAL", 51, 62], ["microneedle-induced channels", "PROTEIN", 117, 145], ["the transdermal permeation", "TEST", 47, 73], ["microneedle-induced channels", "TREATMENT", 117, 145], ["ITP", "PROBLEM", 192, 195], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["ITP", "OBSERVATION", 192, 195]]], ["Ito et al reported sustained-release self-dissolving micropiles (SDMPs), in which porous silicon dioxide and porous calcium silicate were used as nanoporous microparticles to adsorb insulin, and the microparticle-adsorbed insulin was molded to SDMPs using chondroitin sulfate as a base.", [["silicon dioxide", "CHEMICAL", 89, 104], ["calcium silicate", "CHEMICAL", 116, 132], ["chondroitin sulfate", "CHEMICAL", 256, 275], ["silicon dioxide", "CHEMICAL", 89, 104], ["calcium silicate", "CHEMICAL", 116, 132], ["chondroitin sulfate", "CHEMICAL", 256, 275], ["micropiles", "SIMPLE_CHEMICAL", 53, 63], ["SDMPs", "SIMPLE_CHEMICAL", 65, 70], ["silicon dioxide", "SIMPLE_CHEMICAL", 89, 104], ["porous calcium silicate", "SIMPLE_CHEMICAL", 109, 132], ["insulin", "GENE_OR_GENE_PRODUCT", 182, 189], ["microparticle", "SIMPLE_CHEMICAL", 199, 212], ["insulin", "GENE_OR_GENE_PRODUCT", 222, 229], ["SDMPs", "SIMPLE_CHEMICAL", 244, 249], ["chondroitin sulfate", "SIMPLE_CHEMICAL", 256, 275], ["insulin", "PROTEIN", 182, 189], ["insulin", "PROTEIN", 222, 229], ["porous silicon dioxide and porous calcium silicate", "TREATMENT", 82, 132], ["nanoporous microparticles to adsorb insulin", "TREATMENT", 146, 189], ["the microparticle-adsorbed insulin", "TREATMENT", 195, 229], ["chondroitin sulfate", "TREATMENT", 256, 275]]], ["They concluded that long-acting SDMP preparation would be possible by means of porous silicate adsorbent-held insulin.30Biodegradable microneedles ::: Drug and vaccine delivery methods via the skinBiodegradable microneedles, mostly using different kinds of biodegradable polymers, including polylactic acid, chitosan, polyglycolic acid, or poly(lactide-co-glycolide) (PLGA) to form the matrix, degrade in the skin after application, whereby the release of incorporated drugs can be sustained for months by choosing the proper polymer.", [["matrix", "ANATOMY", 386, 392], ["skin", "ANATOMY", 409, 413], ["SDMP", "CHEMICAL", 32, 36], ["polylactic acid", "CHEMICAL", 291, 306], ["chitosan", "CHEMICAL", 308, 316], ["polyglycolic acid", "CHEMICAL", 318, 335], ["poly(lactide-co-glycolide", "CHEMICAL", 340, 365], ["PLGA", "CHEMICAL", 368, 372], ["silicate", "CHEMICAL", 86, 94], ["polylactic acid", "CHEMICAL", 291, 306], ["polyglycolic acid", "CHEMICAL", 318, 335], ["poly(lactide-co-glycolide)", "CHEMICAL", 340, 366], ["PLGA", "CHEMICAL", 368, 372], ["SDMP", "SIMPLE_CHEMICAL", 32, 36], ["insulin", "GENE_OR_GENE_PRODUCT", 110, 117], ["polylactic acid", "SIMPLE_CHEMICAL", 291, 306], ["chitosan", "SIMPLE_CHEMICAL", 308, 316], ["polyglycolic acid", "SIMPLE_CHEMICAL", 318, 335], ["poly(lactide-co-glycolide)", "SIMPLE_CHEMICAL", 340, 366], ["PLGA", "SIMPLE_CHEMICAL", 368, 372], ["matrix", "CELLULAR_COMPONENT", 386, 392], ["skin", "ORGAN", 409, 413], ["insulin", "PROTEIN", 110, 117], ["long-acting SDMP preparation", "TREATMENT", 20, 48], ["porous silicate adsorbent", "TREATMENT", 79, 104], ["insulin", "TREATMENT", 110, 117], ["Drug and vaccine delivery methods", "TREATMENT", 151, 184], ["the skinBiodegradable microneedles", "TREATMENT", 189, 223], ["biodegradable polymers", "TREATMENT", 257, 279], ["polylactic acid, chitosan", "TREATMENT", 291, 316], ["polyglycolic acid", "TREATMENT", 318, 335], ["poly(lactide-co-glycolide)", "TREATMENT", 340, 366], ["the matrix", "PROBLEM", 382, 392], ["incorporated drugs", "TREATMENT", 456, 474], ["biodegradable polymers", "OBSERVATION", 257, 279], ["skin", "ANATOMY", 409, 413]]], ["A previous study demonstrated the possibility of these biodegradable microneedles as a patient-friendly substitute for conventional sustained-delivery methods.31 However, these microneedles must be inserted and remain in the skin for several days to utilize the degradation property of biodegradable polymer effectively.Biodegradable microneedles ::: Drug and vaccine delivery methods via the skinKim et al32 demonstrated that microneedle separation into the skin was mediated by hydrogel swelling in response to contact with body fluid after the needles were inserted into the skin.", [["skin", "ANATOMY", 225, 229], ["skin", "ANATOMY", 459, 463], ["body fluid", "ANATOMY", 526, 536], ["needles", "ANATOMY", 547, 554], ["skin", "ANATOMY", 578, 582], ["patient", "ORGANISM", 87, 94], ["skin", "ORGAN", 225, 229], ["Drug", "SIMPLE_CHEMICAL", 351, 355], ["skin", "ORGAN", 459, 463], ["body fluid", "ORGANISM_SUBSTANCE", 526, 536], ["skin", "ORGAN", 578, 582], ["patient", "SPECIES", 87, 94], ["A previous study", "TEST", 0, 16], ["these biodegradable microneedles", "TREATMENT", 49, 81], ["conventional sustained-delivery methods", "TREATMENT", 119, 158], ["these microneedles", "TREATMENT", 171, 189], ["the degradation property of biodegradable polymer effectively", "TREATMENT", 258, 319], ["Biodegradable microneedles", "TREATMENT", 320, 346], ["Drug and vaccine delivery methods", "TREATMENT", 351, 384], ["the skinKim et al32", "TREATMENT", 389, 408], ["microneedle separation into the skin", "PROBLEM", 427, 463], ["hydrogel swelling", "PROBLEM", 480, 497], ["the needles", "TREATMENT", 543, 554], ["skin", "ANATOMY", 225, 229], ["biodegradable polymer", "OBSERVATION", 286, 307], ["skin", "ANATOMY", 459, 463], ["hydrogel swelling", "OBSERVATION", 480, 497], ["skin", "ANATOMY", 578, 582]]], ["The hydrogel particles absorbed water quickly, resulting in the cracking of the microneedles due to the difference in volume expansion between the needle-matrix polymer and the hydrogel particles.", [["The hydrogel particles", "TREATMENT", 0, 22], ["the microneedles", "TREATMENT", 76, 92], ["the difference in volume expansion", "PROBLEM", 100, 134], ["the needle-matrix polymer", "TREATMENT", 143, 168], ["the hydrogel particles", "TREATMENT", 173, 195], ["hydrogel", "OBSERVATION_MODIFIER", 4, 12], ["particles", "OBSERVATION_MODIFIER", 13, 22], ["absorbed", "OBSERVATION_MODIFIER", 23, 31], ["cracking", "OBSERVATION_MODIFIER", 64, 72], ["volume expansion", "OBSERVATION", 118, 134], ["hydrogel particles", "OBSERVATION", 177, 195]]], ["The swollen particles caused the microneedles to totally break down, leaving the microneedle tips in the porcine cadaver skin in vitro and in the hairless mouse skin in vivo (Figure 3).", [["swollen particles", "ANATOMY", 4, 21], ["skin", "ANATOMY", 121, 125], ["skin", "ANATOMY", 161, 165], ["porcine", "ORGANISM", 105, 112], ["cadaver", "TISSUE", 113, 120], ["skin", "ORGAN", 121, 125], ["mouse", "ORGANISM", 155, 160], ["skin", "ORGAN", 161, 165], ["porcine", "SPECIES", 105, 112], ["mouse", "SPECIES", 155, 160], ["mouse", "SPECIES", 155, 160], ["The swollen particles", "PROBLEM", 0, 21], ["the microneedles", "TREATMENT", 29, 45], ["the microneedle tips", "TREATMENT", 77, 97], ["the porcine cadaver skin in vitro", "TREATMENT", 101, 134], ["swollen", "OBSERVATION_MODIFIER", 4, 11], ["particles", "OBSERVATION", 12, 21], ["microneedle", "OBSERVATION_MODIFIER", 81, 92], ["tips", "OBSERVATION_MODIFIER", 93, 97], ["porcine", "ANATOMY_MODIFIER", 105, 112], ["cadaver", "ANATOMY_MODIFIER", 113, 120], ["skin", "ANATOMY", 121, 125], ["hairless mouse", "ANATOMY", 146, 160], ["skin", "ANATOMY", 161, 165]]], ["Chu et al33 introduced separable arrowhead microneedles that featured micron-size sharp tips mounted on blunt shafts.", [["separable arrowhead microneedles", "TREATMENT", 23, 55], ["blunt shafts", "PROBLEM", 104, 116], ["micron", "OBSERVATION_MODIFIER", 70, 76], ["size", "OBSERVATION_MODIFIER", 77, 81], ["sharp", "OBSERVATION_MODIFIER", 82, 87], ["tips", "OBSERVATION_MODIFIER", 88, 92], ["blunt shafts", "OBSERVATION", 104, 116]]], ["Upon insertion in the skin, the sharp-tipped polymer arrowheads encapsulating drug separate from their metal shafts and remain embedded in the skin for subsequent dissolution and drug release.", [["skin", "ANATOMY", 22, 26], ["skin", "ANATOMY", 143, 147], ["skin", "ORGAN", 22, 26], ["skin", "ORGAN", 143, 147], ["the sharp-tipped polymer arrowheads encapsulating drug", "TREATMENT", 28, 82], ["their metal shafts", "TREATMENT", 97, 115], ["subsequent dissolution and drug release", "TREATMENT", 152, 191], ["insertion", "OBSERVATION", 5, 14], ["skin", "ANATOMY", 22, 26], ["sharp", "OBSERVATION_MODIFIER", 32, 37], ["metal shafts", "OBSERVATION", 103, 115], ["skin", "ANATOMY", 143, 147]]], ["The blunt metal shafts can then be discarded.", [["The blunt metal shafts", "TREATMENT", 0, 22], ["blunt", "OBSERVATION_MODIFIER", 4, 9], ["metal shafts", "OBSERVATION", 10, 22]]], ["Due to rapid separation of the arrowhead tips from the shafts within seconds, administration using arrowhead microneedles can be carried out rapidly, while drug-release kinetics can be independently controlled, based on separable arrowhead formulation (Figure 4).", [["the arrowhead tips", "TREATMENT", 27, 45], ["administration using arrowhead microneedles", "TREATMENT", 78, 121], ["drug-release kinetics", "TREATMENT", 156, 177], ["rapid", "OBSERVATION_MODIFIER", 7, 12], ["separation", "OBSERVATION_MODIFIER", 13, 23], ["tips", "OBSERVATION_MODIFIER", 41, 45], ["shafts", "ANATOMY_MODIFIER", 55, 61]]], ["Park et al31 developed arrays of microneedles that were fabricated out of PLGA using a mold-based technique to encapsulate model drugs \u2013 calcein and bovine serum albumin \u2013 either as a single encapsulation within the needle matrix or as a double encapsulation, by first encapsulating the drug within carboxymethyl cellulose or poly-L-lactide microparticles and then encapsulating drug-loaded microparticles within needles.", [["serum", "ANATOMY", 156, 161], ["PLGA", "CHEMICAL", 74, 78], ["calcein", "CHEMICAL", 137, 144], ["carboxymethyl cellulose", "CHEMICAL", 299, 322], ["poly-L-lactide", "CHEMICAL", 326, 340], ["PLGA", "CHEMICAL", 74, 78], ["calcein", "CHEMICAL", 137, 144], ["carboxymethyl", "CHEMICAL", 299, 312], ["poly-L-lactide", "CHEMICAL", 326, 340], ["PLGA", "SIMPLE_CHEMICAL", 74, 78], ["calcein", "SIMPLE_CHEMICAL", 137, 144], ["bovine", "ORGANISM", 149, 155], ["serum", "ORGANISM_SUBSTANCE", 156, 161], ["albumin", "SIMPLE_CHEMICAL", 162, 169], ["carboxymethyl cellulose", "SIMPLE_CHEMICAL", 299, 322], ["poly-L-lactide microparticles", "SIMPLE_CHEMICAL", 326, 355], ["poly-L-lactide microparticles", "CELL_LINE", 326, 355], ["bovine", "SPECIES", 149, 155], ["arrays of microneedles", "TREATMENT", 23, 45], ["PLGA", "TREATMENT", 74, 78], ["a mold-based technique", "TREATMENT", 85, 107], ["model drugs", "TREATMENT", 123, 134], ["calcein", "TREATMENT", 137, 144], ["bovine serum albumin", "TREATMENT", 149, 169], ["a single encapsulation within the needle matrix", "TREATMENT", 182, 229], ["a double encapsulation", "TREATMENT", 236, 258], ["the drug within carboxymethyl cellulose", "TREATMENT", 283, 322], ["poly-L-lactide microparticles", "TREATMENT", 326, 355], ["encapsulating drug-loaded microparticles within needles", "TREATMENT", 365, 420]]], ["In vitro release of calcein and bovine serum albumin from three different encapsulation formulations was measured over time, and was shown to be controlled by the encapsulation method to achieve release kinetics ranging from hours to months.", [["serum", "ANATOMY", 39, 44], ["calcein", "CHEMICAL", 20, 27], ["calcein", "CHEMICAL", 20, 27], ["calcein", "SIMPLE_CHEMICAL", 20, 27], ["bovine", "ORGANISM", 32, 38], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["albumin", "SIMPLE_CHEMICAL", 45, 52], ["bovine", "SPECIES", 32, 38], ["bovine", "SPECIES", 32, 38], ["calcein", "TREATMENT", 20, 27], ["bovine serum albumin", "TEST", 32, 52], ["three different encapsulation formulations", "TREATMENT", 58, 100], ["the encapsulation method", "TREATMENT", 159, 183]]], ["Tsioris et al34 reported on a fabrication method to produce silk biopolymer microstructures with the high aspect ratios required to manufacture microneedle systems.", [["a fabrication method", "TREATMENT", 28, 48], ["silk biopolymer microstructures", "TREATMENT", 60, 91], ["the high aspect ratios", "TREATMENT", 97, 119]]], ["Room temperature and aqueous-based micromolding allow for the bulk loading of these microneedle structures with temperature-sensitive drugs such as peptides, antibiotics, and vaccines, or any temperature-labile therapeutic.", [["aqueous-based micromolding", "TREATMENT", 21, 47], ["temperature-sensitive drugs", "TREATMENT", 112, 139], ["peptides", "TREATMENT", 148, 156], ["antibiotics", "TREATMENT", 158, 169], ["vaccines", "TREATMENT", 175, 183], ["any temperature", "TEST", 188, 203]]], ["Controlled release of a model drug is achieved by adjusting the postprocessing conditions of the microneedle structures, mainly by controlling the silk protein secondary structure.Biodegradable microneedles ::: Drug and vaccine delivery methods via the skinAusiello et al35 released a method for extended and controlled delivery of parathyroid hormone to a patient in need, involving implanting a medical device into the patient, the medical device comprising a substrate, a plurality of reservoirs in the substrate, and a release system contained in each of the reservoirs, wherein the release system comprised parathyroid hormone, and controllably releasing a pharmaceutically effective amount of the parathyroid hormone from the reservoirs.Biodegradable microneedles ::: Drug and vaccine delivery methods via the skinMicroneedle delivery of nucleic acids, in particular plasmid DNA (pDNA), to the skin represents a potential new approach for the clinical management of genetic skin diseases and cutaneous cancers, and for intracutaneous genetic immunization.", [["plasmid", "ANATOMY", 873, 880], ["skin", "ANATOMY", 900, 904], ["skin", "ANATOMY", 980, 984], ["cutaneous cancers", "ANATOMY", 998, 1015], ["nucleic acids", "CHEMICAL", 844, 857], ["skin diseases", "DISEASE", 980, 993], ["cutaneous cancers", "DISEASE", 998, 1015], ["parathyroid hormone", "GENE_OR_GENE_PRODUCT", 332, 351], ["patient", "ORGANISM", 357, 364], ["patient", "ORGANISM", 421, 428], ["parathyroid", "ORGAN", 612, 623], ["parathyroid hormone", "GENE_OR_GENE_PRODUCT", 703, 722], ["skinMicroneedle", "SIMPLE_CHEMICAL", 816, 831], ["nucleic acids", "SIMPLE_CHEMICAL", 844, 857], ["DNA", "CELLULAR_COMPONENT", 881, 884], ["pDNA", "CELLULAR_COMPONENT", 886, 890], ["skin", "ORGAN", 900, 904], ["skin", "ORGAN", 980, 984], ["cutaneous cancers", "CANCER", 998, 1015], ["silk protein secondary structure", "PROTEIN", 147, 179], ["plasmid DNA", "DNA", 873, 884], ["patient", "SPECIES", 357, 364], ["patient", "SPECIES", 421, 428], ["a model drug", "TREATMENT", 22, 34], ["the microneedle structures", "TREATMENT", 93, 119], ["Biodegradable microneedles", "TREATMENT", 180, 206], ["Drug and vaccine delivery methods", "TREATMENT", 211, 244], ["the skinAusiello et al35", "TREATMENT", 249, 273], ["a method", "TREATMENT", 283, 291], ["parathyroid hormone", "TREATMENT", 332, 351], ["a medical device", "TREATMENT", 395, 411], ["the medical device", "TREATMENT", 430, 448], ["a release system", "TREATMENT", 521, 537], ["Biodegradable microneedles", "TREATMENT", 743, 769], ["Drug and vaccine delivery methods", "TREATMENT", 774, 807], ["the skinMicroneedle delivery", "TREATMENT", 812, 840], ["nucleic acids", "TREATMENT", 844, 857], ["the clinical management", "TREATMENT", 945, 968], ["genetic skin diseases", "PROBLEM", 972, 993], ["cutaneous cancers", "PROBLEM", 998, 1015], ["intracutaneous genetic immunization", "TREATMENT", 1025, 1060], ["secondary structure", "OBSERVATION", 160, 179], ["reservoirs", "OBSERVATION", 488, 498], ["reservoirs", "ANATOMY_MODIFIER", 563, 573], ["parathyroid hormone", "OBSERVATION", 612, 631], ["pharmaceutically", "OBSERVATION_MODIFIER", 662, 678], ["effective", "OBSERVATION_MODIFIER", 679, 688], ["amount", "OBSERVATION_MODIFIER", 689, 695], ["parathyroid hormone", "OBSERVATION", 703, 722], ["reservoirs", "OBSERVATION_MODIFIER", 732, 742], ["nucleic acids", "OBSERVATION", 844, 857], ["skin", "ANATOMY", 900, 904], ["skin", "ANATOMY", 980, 984], ["diseases", "OBSERVATION", 985, 993], ["cutaneous", "ANATOMY", 998, 1007], ["cancers", "OBSERVATION", 1008, 1015]]], ["DNA vaccines have many potential benefits, but have failed to generate robust immune responses in humans.36 DeMuth et al37 reported an approach for rapid implantation of vaccine-loaded polymer films carrying DNA, immune-stimulatory RNA, and biodegradable polycations using microneedles coated with releasable polyelectrolyte multilayers that promoted local transfection and controlled the persistence of DNA and adjuvants in the skin from days to weeks, with kinetics determined by the film composition.", [["skin", "ANATOMY", 429, 433], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["humans", "ORGANISM", 98, 104], ["polymer films", "SIMPLE_CHEMICAL", 185, 198], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["polyelectrolyte multilayers", "SIMPLE_CHEMICAL", 309, 336], ["DNA", "CELLULAR_COMPONENT", 404, 407], ["skin", "ORGAN", 429, 433], ["humans", "SPECIES", 98, 104], ["humans", "SPECIES", 98, 104], ["DNA vaccines", "TREATMENT", 0, 12], ["an approach", "TREATMENT", 132, 143], ["rapid implantation of vaccine", "TREATMENT", 148, 177], ["loaded polymer films carrying DNA", "TREATMENT", 178, 211], ["immune-stimulatory RNA", "TREATMENT", 213, 235], ["biodegradable polycations using microneedles", "TREATMENT", 241, 285], ["releasable polyelectrolyte multilayers", "TREATMENT", 298, 336], ["local transfection", "TREATMENT", 351, 369], ["DNA", "PROBLEM", 404, 407], ["adjuvants", "TREATMENT", 412, 421], ["the film composition", "TEST", 482, 502], ["polyelectrolyte multilayers", "OBSERVATION", 309, 336], ["local transfection", "OBSERVATION", 351, 369], ["skin", "ANATOMY", 429, 433]]], ["These \u201cmultilayer tattoo\u201d DNA vaccines induced immune responses against a model HIV antigen comparable to electroporation in mice, enhanced memory T-cell generation, and elicited 140-fold higher gene expression in nonhuman primate skin than intradermal DNA injection, indicating the potential of this strategy for enhancing DNA vaccination (Figure 5).", [["memory T-cell", "ANATOMY", 140, 153], ["skin", "ANATOMY", 231, 235], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["HIV", "ORGANISM", 80, 83], ["mice", "ORGANISM", 125, 129], ["memory T-cell", "CELL", 140, 153], ["nonhuman", "ORGANISM", 214, 222], ["primate", "ORGANISM", 223, 230], ["skin", "ORGAN", 231, 235], ["DNA", "CELLULAR_COMPONENT", 253, 256], ["DNA", "CELLULAR_COMPONENT", 324, 327], ["mice", "SPECIES", 125, 129], ["HIV", "SPECIES", 80, 83], ["mice", "SPECIES", 125, 129], ["These \u201cmultilayer tattoo\u201d DNA vaccines", "TREATMENT", 0, 38], ["immune responses", "PROBLEM", 47, 63], ["a model HIV antigen", "PROBLEM", 72, 91], ["intradermal DNA injection", "TREATMENT", 241, 266], ["this strategy", "TREATMENT", 296, 309], ["enhancing DNA vaccination", "TREATMENT", 314, 339], ["skin", "ANATOMY", 231, 235]]], ["Marc Pearton et al38 proved that the pDNA-coated microneedles facilitated reporter-gene expression in viable human skin, whilst the efficiency of gene expression from coated microneedles will depend upon suitable DNA loading, efficient and reproducible skin puncture, and rapid in situ dissolution of the plasmid at the site of delivery.Microneedle-fabricating methodsFabrication of microneedles usually follows the steps of molding, preparation of microneedle matrix, casting, removal, and drying.39 The concrete methods are determined by the desired property of the microneedles.", [["skin", "ANATOMY", 115, 119], ["skin", "ANATOMY", 253, 257], ["plasmid", "ANATOMY", 305, 312], ["pDNA", "CHEMICAL", 37, 41], ["pDNA", "GENE_OR_GENE_PRODUCT", 37, 41], ["human", "ORGANISM", 109, 114], ["skin", "ORGAN", 115, 119], ["DNA", "CELLULAR_COMPONENT", 213, 216], ["skin", "ORGAN", 253, 257], ["plasmid", "DNA", 305, 312], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["Marc Pearton et al38", "TREATMENT", 0, 20], ["the pDNA-coated microneedles facilitated reporter", "TREATMENT", 33, 82], ["gene expression from coated microneedles", "TREATMENT", 146, 186], ["suitable DNA loading", "TREATMENT", 204, 224], ["reproducible skin puncture", "TREATMENT", 240, 266], ["the plasmid", "TREATMENT", 301, 312], ["delivery", "TREATMENT", 328, 336], ["Microneedle-fabricating methodsFabrication of microneedles", "TREATMENT", 337, 395], ["molding", "TREATMENT", 425, 432], ["preparation of microneedle matrix", "TREATMENT", 434, 467], ["casting", "TREATMENT", 469, 476], ["removal", "TREATMENT", 478, 485], ["skin", "ANATOMY", 115, 119], ["skin", "ANATOMY", 253, 257], ["puncture", "OBSERVATION", 258, 266]]], ["However, harsh fabrication methods (ie, using high temperature or organic solvent) may damage temperature-sensitive drugs, particularly peptides and proteins, so this review mainly focuses on mild fabrication methods.", [["harsh fabrication methods", "TREATMENT", 9, 34], ["high temperature or organic solvent", "TREATMENT", 46, 81], ["damage temperature", "PROBLEM", 87, 105], ["sensitive drugs", "TREATMENT", 106, 121], ["mild fabrication methods", "TREATMENT", 192, 216], ["mild", "OBSERVATION_MODIFIER", 192, 196], ["fabrication", "OBSERVATION", 197, 208]]], ["Vacuum and centrifugation are often applied in casting the microneedle matrix into the molds.", [["Vacuum and centrifugation", "TREATMENT", 0, 25], ["casting the microneedle matrix", "TREATMENT", 47, 77], ["centrifugation", "OBSERVATION", 11, 25], ["molds", "OBSERVATION", 87, 92]]], ["Whilst a polydimethylsiloxane micromold can be created with precise morphological fidelity to master microneedle structures, sugar solutions did not completely fill the micromold invaginations, due to the high surface tension of the solution.", [["surface", "ANATOMY", 210, 217], ["polydimethylsiloxane", "CHEMICAL", 9, 29], ["polydimethylsiloxane", "CHEMICAL", 9, 29], ["sugar", "CHEMICAL", 125, 130], ["polydimethylsiloxane micromold", "SIMPLE_CHEMICAL", 9, 39], ["sugar", "SIMPLE_CHEMICAL", 125, 130], ["a polydimethylsiloxane micromold", "TREATMENT", 7, 39], ["sugar solutions", "TREATMENT", 125, 140], ["the micromold invaginations", "PROBLEM", 165, 192], ["the solution", "TREATMENT", 229, 241]]], ["Martin et al40 revealed a simple and novel low-temperature vacuum-deposition micromolding methodology for biodegradable sugar-glass microneedle fabrication.", [["sugar", "CHEMICAL", 120, 125], ["sugar", "SIMPLE_CHEMICAL", 120, 125], ["Martin et al40", "TEST", 0, 14], ["novel low-temperature vacuum-deposition micromolding methodology", "TREATMENT", 37, 101], ["biodegradable sugar-glass microneedle fabrication", "TREATMENT", 106, 155]]], ["In the original vacuum-oven method, vacuum pressure could not be applied before the sugar solution was placed on the mold surface.", [["surface", "ANATOMY", 122, 129], ["sugar", "CHEMICAL", 84, 89], ["sugar", "SIMPLE_CHEMICAL", 84, 89], ["the original vacuum-oven method", "TREATMENT", 3, 34], ["vacuum pressure", "TREATMENT", 36, 51], ["the sugar solution", "TREATMENT", 80, 98], ["vacuum", "OBSERVATION", 16, 22], ["vacuum pressure", "OBSERVATION", 36, 51], ["mold", "OBSERVATION_MODIFIER", 117, 121], ["surface", "OBSERVATION_MODIFIER", 122, 129]]], ["Subsequently, when the droplet of sugar solution was applied, air was entrapped within the micromold invaginations.", [["micromold invaginations", "ANATOMY", 91, 114], ["sugar", "CHEMICAL", 34, 39], ["sugar", "SIMPLE_CHEMICAL", 34, 39], ["the droplet of sugar solution", "TREATMENT", 19, 48], ["air", "PROBLEM", 62, 65], ["air", "OBSERVATION", 62, 65], ["micromold invaginations", "OBSERVATION", 91, 114]]], ["An optimized method was developed whereby a vacuum was produced within an enclosed chamber before the sugar solution was applied to the mold surface.Microneedle-fabricating methodsDeMuth et al41 developed microneedle-fabrication methods featuring drug-loaded PLGA microparticles or solid PLGA tips.", [["surface", "ANATOMY", 141, 148], ["PLGA microparticles", "CHEMICAL", 259, 278], ["sugar", "CHEMICAL", 102, 107], ["PLGA", "CHEMICAL", 259, 263], ["PLGA", "CHEMICAL", 288, 292], ["sugar", "SIMPLE_CHEMICAL", 102, 107], ["PLGA microparticles", "SIMPLE_CHEMICAL", 259, 278], ["An optimized method", "TREATMENT", 0, 19], ["a vacuum", "TREATMENT", 42, 50], ["the sugar solution", "TREATMENT", 98, 116], ["Microneedle-fabricating methodsDeMuth et al41", "TREATMENT", 149, 194], ["microneedle-fabrication methods", "TREATMENT", 205, 236], ["drug-loaded PLGA microparticles", "TREATMENT", 247, 278], ["solid PLGA tips", "TREATMENT", 282, 297], ["vacuum", "OBSERVATION", 44, 50], ["chamber", "OBSERVATION_MODIFIER", 83, 90], ["mold", "OBSERVATION_MODIFIER", 136, 140], ["surface", "OBSERVATION_MODIFIER", 141, 148], ["solid PLGA tips", "OBSERVATION", 282, 297]]], ["PLGA microparticles were applied to the surface of the mold in an aqueous suspension and compacted into the mold cavities through centrifugation.", [["surface", "ANATOMY", 40, 47], ["PLGA", "CHEMICAL", 0, 4], ["PLGA", "CHEMICAL", 0, 4], ["PLGA microparticles", "SIMPLE_CHEMICAL", 0, 19], ["PLGA microparticles", "TREATMENT", 0, 19], ["an aqueous suspension", "TREATMENT", 63, 84], ["surface", "OBSERVATION_MODIFIER", 40, 47], ["mold", "OBSERVATION_MODIFIER", 55, 59], ["aqueous suspension", "OBSERVATION", 66, 84], ["mold cavities", "OBSERVATION", 108, 121], ["centrifugation", "OBSERVATION_MODIFIER", 130, 144]]], ["Excess microparticles were then removed, and the microparticle-loaded mold was allowed to dry.", [["microparticle", "SIMPLE_CHEMICAL", 49, 62], ["Excess microparticles", "PROBLEM", 0, 21], ["the microparticle-loaded mold", "TREATMENT", 45, 74], ["microparticles", "OBSERVATION", 7, 21]]], ["Then, a concentrated aqueous solution of poly(acrylic acid) was added to the mold surface and infiltrated into the packed PLGA particle bed via centrifugation.", [["mold surface", "ANATOMY", 77, 89], ["poly(acrylic acid", "CHEMICAL", 41, 58], ["poly(acrylic acid)", "CHEMICAL", 41, 59], ["PLGA", "CHEMICAL", 122, 126], ["poly(acrylic acid", "SIMPLE_CHEMICAL", 41, 58], ["a concentrated aqueous solution of poly(acrylic acid)", "TREATMENT", 6, 59], ["the packed PLGA particle", "TREATMENT", 111, 135], ["packed", "OBSERVATION_MODIFIER", 115, 121], ["PLGA particle", "OBSERVATION", 122, 135]]], ["After being dried under vacuum, a solid PLGA-poly(acrylic acid) microparticle matrix was obtained.", [["PLGA-poly(acrylic acid", "CHEMICAL", 40, 62], ["PLGA", "CHEMICAL", 40, 44], ["poly(acrylic acid)", "CHEMICAL", 45, 63], ["solid PLGA-poly(acrylic acid", "SIMPLE_CHEMICAL", 34, 62], ["vacuum", "TREATMENT", 24, 30], ["a solid PLGA-poly(acrylic acid) microparticle matrix", "TREATMENT", 32, 84]]], ["If the microparticle-loaded polydimethylsiloxane molds were dried and incubated under vacuum to fuse the embedded PLGA particles, solidified PLGA tips were obtained.", [["polydimethylsiloxane molds", "CHEMICAL", 28, 54], ["PLGA", "CHEMICAL", 114, 118], ["PLGA", "CHEMICAL", 141, 145], ["polydimethylsiloxane", "CHEMICAL", 28, 48], ["PLGA", "CHEMICAL", 114, 118], ["PLGA", "CHEMICAL", 141, 145], ["microparticle", "SIMPLE_CHEMICAL", 7, 20], ["polydimethylsiloxane molds", "SIMPLE_CHEMICAL", 28, 54], ["PLGA particles", "SIMPLE_CHEMICAL", 114, 128], ["PLGA tips", "SIMPLE_CHEMICAL", 141, 150], ["the microparticle-loaded polydimethylsiloxane molds", "TREATMENT", 3, 54], ["vacuum", "TREATMENT", 86, 92], ["the embedded PLGA particles", "TREATMENT", 101, 128], ["solidified PLGA tips", "TREATMENT", 130, 150], ["polydimethylsiloxane molds", "OBSERVATION", 28, 54], ["PLGA particles", "OBSERVATION", 114, 128], ["PLGA tips", "OBSERVATION", 141, 150]]], ["DeMuth et al37 demonstrated a new approach for DNA vaccination via multilayer \u201ctattooing,\u201d using microneedles employing a pH-responsive release layer to implant biodegradable vaccine-loaded polymer films rapidly into the skin.Microneedle-fabricating methodsMefti et al released a patent concerning the administration of drugs with microneedles.", [["skin", "ANATOMY", 221, 225], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["polymer films", "SIMPLE_CHEMICAL", 190, 203], ["skin", "ORGAN", 221, 225], ["DNA vaccination", "TREATMENT", 47, 62], ["multilayer \u201ctattooing", "TREATMENT", 67, 88], ["microneedles", "TREATMENT", 97, 109], ["a pH-responsive release layer", "TREATMENT", 120, 149], ["implant biodegradable vaccine-loaded polymer films", "TREATMENT", 153, 203], ["Microneedle-fabricating methodsMefti et al", "TREATMENT", 226, 268], ["drugs with microneedles", "TREATMENT", 320, 343], ["skin", "ANATOMY", 221, 225], ["patent", "OBSERVATION", 280, 286]]], ["More specifically, it concerned microneedles comprising a part that dissolves by hydrolysis once they have penetrated the skin.42Microneedle-fabricating methodsIt can also be concluded that enhancing methods such as ITP, as well as with different drug carriers (eg, micro-and nanoparticles) will be applied to the fabrication of microneedles.43PerspectivesMicroneedles effectively circumvent the skin barrier to offer this route as a potential alternative to oral and parenteral delivery of therapeutics,44 and relatively large doses can be administered due to bulk loading of dissolvable or biodegradable systems.", [["skin", "ANATOMY", 122, 126], ["skin", "ANATOMY", 396, 400], ["oral", "ANATOMY", 459, 463], ["ITP", "DISEASE", 216, 219], ["skin", "ORGAN", 122, 126], ["skin barrier", "TISSUE", 396, 408], ["oral", "ORGANISM_SUBDIVISION", 459, 463], ["enhancing methods", "PROBLEM", 190, 207], ["ITP", "PROBLEM", 216, 219], ["different drug carriers", "TREATMENT", 237, 260], ["micro-and nanoparticles)", "TREATMENT", 266, 290], ["the fabrication of microneedles", "TREATMENT", 310, 341], ["43PerspectivesMicroneedles", "TREATMENT", 342, 368], ["the skin barrier", "TREATMENT", 392, 408], ["this route", "TREATMENT", 418, 428], ["oral and parenteral delivery of therapeutics", "TREATMENT", 459, 503], ["bulk loading of dissolvable or biodegradable systems", "PROBLEM", 561, 613], ["skin", "ANATOMY", 122, 126], ["enhancing", "OBSERVATION_MODIFIER", 190, 199], ["skin", "ANATOMY", 396, 400]]], ["However, there are still several problems that remain to be solved.", [["still several problems", "PROBLEM", 19, 41], ["several", "OBSERVATION_MODIFIER", 25, 32], ["problems", "OBSERVATION", 33, 41]]], ["For example, the barrier function of the skin changes from one site to another on the same person, from person to person, and with age.45 It is important to ensure that patients obtain the same and required dose during each microneedle administration, since the difference in individual skin and the penetration depth of microneedles relate to the stress upon the skin, thus an applicator may be required in order to obtain a reproducible penetration depth.", [["skin", "ANATOMY", 41, 45], ["skin", "ANATOMY", 287, 291], ["skin", "ANATOMY", 364, 368], ["skin", "ORGAN", 41, 45], ["patients", "ORGANISM", 169, 177], ["skin", "ORGAN", 287, 291], ["skin", "ORGAN", 364, 368], ["person", "SPECIES", 91, 97], ["person", "SPECIES", 104, 110], ["person", "SPECIES", 114, 120], ["patients", "SPECIES", 169, 177], ["the skin changes", "PROBLEM", 37, 53], ["each microneedle administration", "TREATMENT", 219, 250], ["the difference in individual skin", "PROBLEM", 258, 291], ["the stress upon the skin", "PROBLEM", 344, 368], ["an applicator", "TREATMENT", 375, 388], ["a reproducible penetration depth", "PROBLEM", 424, 456], ["skin", "ANATOMY", 41, 45], ["skin", "ANATOMY", 287, 291], ["skin", "ANATOMY", 364, 368], ["reproducible", "OBSERVATION_MODIFIER", 426, 438], ["penetration", "OBSERVATION", 439, 450]]], ["Besides, the sustained release of drugs or vaccines is more complicated than bolus release, and the kinetics should be further investigated and ensured.", [["drugs", "TREATMENT", 34, 39], ["vaccines", "TREATMENT", 43, 51], ["bolus release", "TREATMENT", 77, 90], ["the kinetics", "TREATMENT", 96, 108]]], ["It is also necessary to investigate whether dissolved or degraded matrices have side effects if microneedles are used frequently.", [["microneedles", "TREATMENT", 96, 108]]], ["Although these materials are commonly seen excipients in drugs, the accumulation levels and their influences should be noted for prudential reasons.", [["drugs", "TREATMENT", 57, 62], ["the accumulation levels", "PROBLEM", 64, 87], ["accumulation levels", "OBSERVATION", 68, 87]]], ["In addition, in some microneedle-fabrication cases, the polymer-melting temperatures were above 135\u00b0C and vacuum necessary for processing, and these conditions could be detrimental to various temperature-sensitive drugs, particularly peptides and proteins.", [["C", "GENE_OR_GENE_PRODUCT", 100, 101], ["some microneedle-fabrication cases", "TREATMENT", 16, 50], ["the polymer-melting temperatures", "TEST", 52, 84], ["various temperature", "TEST", 184, 203], ["sensitive drugs", "TREATMENT", 204, 219]]], ["Polymer microneedles for controlled-release delivery are also constrained by needle mechanical properties when the main matrix is PLGA or carboxymethyl cellulose.", [["matrix", "ANATOMY", 120, 126], ["PLGA", "CHEMICAL", 130, 134], ["carboxymethyl cellulose", "CHEMICAL", 138, 161], ["PLGA", "CHEMICAL", 130, 134], ["carboxymethyl", "CHEMICAL", 138, 151], ["matrix", "CELLULAR_COMPONENT", 120, 126], ["PLGA", "SIMPLE_CHEMICAL", 130, 134], ["carboxymethyl cellulose", "SIMPLE_CHEMICAL", 138, 161], ["Polymer microneedles", "TREATMENT", 0, 20], ["controlled-release delivery", "TREATMENT", 25, 52], ["needle mechanical properties", "TREATMENT", 77, 105], ["carboxymethyl cellulose", "TREATMENT", 138, 161], ["main matrix", "ANATOMY", 115, 126]]], ["Park et al found that microneedles with 2% drug loading retained sufficient mechanical strength, but needles with 10% loading did not.", [["microneedles", "TREATMENT", 22, 34], ["2% drug loading", "TREATMENT", 40, 55], ["needles", "TREATMENT", 101, 108], ["mechanical strength", "OBSERVATION", 76, 95]]], ["Although the maximum dose constrains applications, controlled-release delivery of up to 1 mg has a number of candidate drugs on the market, with more likely to be approved in the future.31PerspectivesDNA vaccines have been intensively studied because of potential advantages, such as ease of good-manufacturing-practice production, lack of antivector immunity, and the capability to promote both cellular and humoral immune responses.46,47 Since the discovery48 that genetically engineered DNA can be delivered in vaccine form and elicit an immune response, there has been much progress in understanding the basic biology of this platform.49,50 A large amount of data has been generated in preclinical model systems,51,52 and more sustained cellular responses and more consistent antibody responses are being observed in the clinic.53,54 Microneedle application is promising in promoting local transfection and controlling the persistence of DNA and adjuvants in the skin from days to weeks to function as an optimal strategy for safe, reproducible, and pain-free DNA vaccination.", [["cellular", "ANATOMY", 396, 404], ["cellular", "ANATOMY", 741, 749], ["skin", "ANATOMY", 967, 971], ["pain", "DISEASE", 1054, 1058], ["cellular", "CELL", 396, 404], ["DNA", "CELLULAR_COMPONENT", 490, 493], ["cellular", "CELL", 741, 749], ["DNA", "CELLULAR_COMPONENT", 942, 945], ["skin", "ORGAN", 967, 971], ["DNA", "CELLULAR_COMPONENT", 1064, 1067], ["the maximum dose constrains applications", "TREATMENT", 9, 49], ["controlled-release delivery", "TREATMENT", 51, 78], ["drugs", "TREATMENT", 119, 124], ["31PerspectivesDNA vaccines", "TREATMENT", 186, 212], ["antivector immunity", "TREATMENT", 340, 359], ["Microneedle application", "TREATMENT", 838, 861], ["local transfection", "TREATMENT", 888, 906], ["DNA", "PROBLEM", 942, 945], ["adjuvants", "TREATMENT", 950, 959], ["an optimal strategy", "TREATMENT", 1006, 1025], ["pain", "PROBLEM", 1054, 1058], ["free DNA vaccination", "TREATMENT", 1059, 1079], ["large", "OBSERVATION_MODIFIER", 647, 652], ["amount", "OBSERVATION_MODIFIER", 653, 659], ["cellular responses", "OBSERVATION", 741, 759], ["antibody responses", "OBSERVATION", 780, 798], ["local transfection", "OBSERVATION", 888, 906], ["skin", "ANATOMY", 967, 971]]], ["For therapeutic proteins, preservation of protein structure during manufacture, storage, and use is considered even more important than for vaccines, and unwanted immunogenicity can lead to total loss of the therapeutic effect of a protein by neutralizing antibodies, and may even lead to depletion of endogenous proteins or breaking the immune tolerance to self-antigens.", [["neutralizing antibodies", "PROTEIN", 243, 266], ["endogenous proteins", "PROTEIN", 302, 321], ["therapeutic proteins", "TREATMENT", 4, 24], ["protein structure", "PROBLEM", 42, 59], ["vaccines", "TREATMENT", 140, 148], ["total loss", "PROBLEM", 190, 200], ["a protein by neutralizing antibodies", "TREATMENT", 230, 266], ["endogenous proteins", "PROBLEM", 302, 321], ["breaking the immune tolerance", "PROBLEM", 325, 354], ["protein structure", "OBSERVATION", 42, 59], ["endogenous proteins", "OBSERVATION", 302, 321]]], ["For dissolving microneedles, future studies will partially focus upon the incorporation of other bioactivity-enhancing methods including ITP components into polymeric microneedle devices and investigation of their potential for efficient, electrically controlled pulsatile delivery of macromolecules from drug-loaded dissolving polymeric microneedle arrays.29,35PerspectivesAltogether, dissolving and biodegradable microneedle technologies have a bright future for transdermal sustained delivery of drug and vaccine, and require further studies.55", [["ITP", "DISEASE", 137, 140], ["dissolving microneedles", "TREATMENT", 4, 27], ["future studies", "TEST", 29, 43], ["other bioactivity", "TREATMENT", 91, 108], ["enhancing methods", "TREATMENT", 109, 126], ["ITP components", "TREATMENT", 137, 151], ["polymeric microneedle devices", "TREATMENT", 157, 186], ["electrically controlled pulsatile delivery of macromolecules", "TREATMENT", 239, 299], ["drug-loaded dissolving polymeric microneedle arrays", "TREATMENT", 305, 356], ["dissolving and biodegradable microneedle technologies", "TREATMENT", 386, 439], ["transdermal sustained delivery of drug and vaccine", "TREATMENT", 465, 515], ["further studies", "TEST", 529, 544]]]], "PMC7234950": [["In particular, an interactive web-dashboard from Johns Hopkins University has proven useful in monitoring the outbreak of the pandemic and keeping billions of people informed about current developments [1,2].", [["people", "ORGANISM", 159, 165], ["people", "SPECIES", 159, 165]]], ["As the interaction between operational decision-makers and decision support systems (DSS) largely occurs via graphical user interfaces (GUIs) [3], the design and implemented features of a dashboard are of specific importance for the effectiveness of a DSS, particularly at the operational level [4].", [["DSS", "DISEASE", 252, 255], ["a DSS", "TREATMENT", 250, 255]]], ["However, static dashboards appear no longer sufficient to account for the increased need to analyze complex and multidimensional data at the operational level.", [["multidimensional data", "TEST", 112, 133], ["no longer", "UNCERTAINTY", 34, 43]]], ["The aim is to create interactive dashboards that involve users during data analysis.", [["data analysis", "TEST", 70, 83]]], ["Such dashboards recognize the limits of low human involvement with static dashboards, the high human involvement with interactive dashboards, and value the introduction of interactive analytical features [10].", [["human", "ORGANISM", 44, 49], ["human", "ORGANISM", 95, 100], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 95, 100]]], ["The idea is to solve optimization problems automatically via computational approaches in the backend (analytical component) but to (still) involve the individual in the optimization process via the GUI (interactive component) [11].", [["optimization problems", "PROBLEM", 21, 42], ["computational approaches", "TREATMENT", 61, 85]]], ["Yigitbasioglu and Velcu [4] and Pauwels et al. [9] argue that the promise of interactive analytical features such as a what-if analysis is unrealized in current dashboard solutions for operational DSS.", [["interactive analytical features", "PROBLEM", 77, 108], ["operational DSS", "TREATMENT", 185, 200]]], ["However, by introducing an interactive analytical feature, operational decision-makers can interact with the optimization system without knowing the optimization model or understanding how the optimization procedure behind the results operates [14].", [["the optimization procedure", "TREATMENT", 189, 215]]], ["Such behavior can harm an individual's comprehension of the current situation, nourishing an out-of-the-loop problem\u2014a situation in which a human being lacks sufficient knowledge of particular issues [15].", [["human", "ORGANISM", 140, 145], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145]]], ["381).IntroductionAlthough what-if analyses have been investigated for DSS, empirical results have shown conflicting results.", [["DSS", "TREATMENT", 70, 73]]], ["Benbasat and Dexter [16], as well as Sharda et al. [17], found a positive relationship.", [["Benbasat", "CHEMICAL", 0, 8], ["Benbasat", "CHEMICAL", 0, 8], ["Benbasat", "SIMPLE_CHEMICAL", 0, 8]]], ["However, Fripp [18] and Goslar et al. [19] have demonstrated no statistically significant effect.", [["no", "UNCERTAINTY", 61, 63], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["effect", "OBSERVATION", 90, 96]]], ["In turn, others like Davis et al. [13] found that decision-makers performed better without a what-if analysis.", [["analysis", "TEST", 101, 109]]], ["With these conflicting results, it is surprising that academic literature gives relatively little attention to (1) how interactive analytical dashboard features should appear or (2) how they influence human beings' cognitive abilities in operational DSS [4].", [["human", "ORGANISM", 201, 206], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 201, 206]]], ["An adequate level of situation awareness (SA) is emphasized as a promising starting point to examine this unfolding research gap [20].", [["this unfolding research gap", "PROBLEM", 101, 128], ["adequate", "OBSERVATION_MODIFIER", 3, 11]]], ["Human factors research confirms that human beings' SA represents a key enabler for operational decision-making and task performance [21,22].", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 37, 42], ["Human factors", "PROTEIN", 0, 13], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42]]], ["The objective of this study is, therefore, to examine the relationship between an interactive analytical dashboard feature, human beings' SA, and task performance in operational DSS.", [["DSS", "DISEASE", 178, 181], ["human", "ORGANISM", 124, 129], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129], ["this study", "TEST", 17, 27]]], ["We rely on Endsley's [25] SA model as a theoretical guide for our analysis.", [["our analysis", "TEST", 62, 74]]], ["It is established in academia and has shown favorable outcomes in different studies [21].", [["different studies", "TEST", 66, 83], ["academia", "OBSERVATION", 21, 29], ["favorable", "OBSERVATION_MODIFIER", 44, 53]]]], "51f56783febe69530ae6fb6bd2725cbf0ac490a4": [["The assembly of foot-and-mouth disease virus (FMDV) requires the cleavage of the P12A polyprotein into individual structural proteins by protease 3C.", [["foot-and-mouth disease virus", "ORGANISM", 16, 44], ["FMDV", "ORGANISM", 46, 50], ["P12A", "GENE_OR_GENE_PRODUCT", 81, 85], ["protease 3C", "GENE_OR_GENE_PRODUCT", 137, 148], ["P12A polyprotein", "PROTEIN", 81, 97], ["structural proteins", "PROTEIN", 114, 133], ["protease 3C", "PROTEIN", 137, 148], ["foot-and-mouth disease virus", "SPECIES", 16, 44], ["FMDV", "SPECIES", 46, 50], ["foot-and-mouth disease virus", "SPECIES", 16, 44], ["FMDV", "SPECIES", 46, 50], ["mouth disease virus", "PROBLEM", 25, 44], ["the cleavage", "TREATMENT", 61, 73], ["the P12A polyprotein", "TREATMENT", 77, 97], ["protease 3C", "TREATMENT", 137, 148], ["foot", "ANATOMY", 16, 20], ["mouth", "ANATOMY", 25, 30]]], ["In this study, we constructed a recombinant baculovirus that simultaneously expressed the genes for the P12A and 3C proteins of Asia I FMDV from individual promoters.", [["baculovirus", "ORGANISM", 44, 55], ["P12A", "GENE_OR_GENE_PRODUCT", 104, 108], ["3C", "GENE_OR_GENE_PRODUCT", 113, 115], ["Asia I FMDV", "ORGANISM", 128, 139], ["P12A and 3C proteins", "PROTEIN", 104, 124], ["promoters", "DNA", 156, 165], ["FMDV", "SPECIES", 135, 139], ["baculovirus", "SPECIES", 44, 55], ["Asia I FMDV", "SPECIES", 128, 139], ["this study", "TEST", 3, 13], ["a recombinant baculovirus", "TREATMENT", 30, 55]]], ["The capsid proteins expressed in High Five TM insect cells were processed by viral 3C protease, as shown by Western blotting, and were antigenic, as revealed by their reactivity in an indirect sandwich-ELISA, and by immunofluorescent assay.", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["capsid proteins", "PROTEIN", 4, 19], ["TM insect cells", "CELL_TYPE", 43, 58], ["viral 3C protease", "PROTEIN", 77, 94], ["The capsid proteins", "TEST", 0, 19], ["High Five TM insect cells", "TREATMENT", 33, 58], ["viral 3C protease", "TREATMENT", 77, 94], ["Western blotting", "TEST", 108, 124], ["an indirect sandwich-ELISA", "TEST", 181, 207], ["immunofluorescent assay", "TEST", 216, 239], ["High Five", "OBSERVATION_MODIFIER", 33, 42], ["viral 3C", "OBSERVATION", 77, 85]]], ["The empty capsid-like particles were similar to authentic 75S empty capsids from FMDV in terms of their shape, size and sedimentation velocity, as demonstrated by sucrose gradient centrifugation.", [["sucrose", "CHEMICAL", 163, 170], ["sucrose", "CHEMICAL", 163, 170], ["FMDV", "ORGANISM", 81, 85], ["sucrose", "SIMPLE_CHEMICAL", 163, 170], ["FMDV", "SPECIES", 81, 85], ["FMDV", "SPECIES", 81, 85], ["The empty capsid-like particles", "TREATMENT", 0, 31], ["sedimentation velocity", "TEST", 120, 142], ["sucrose gradient centrifugation", "TREATMENT", 163, 194], ["empty capsid", "OBSERVATION", 4, 16], ["empty capsids", "OBSERVATION", 62, 75], ["shape", "OBSERVATION_MODIFIER", 104, 109], ["size", "OBSERVATION_MODIFIER", 111, 115], ["sedimentation velocity", "OBSERVATION", 120, 142], ["sucrose", "OBSERVATION", 163, 170], ["gradient centrifugation", "OBSERVATION", 171, 194]]], ["Both empty capsid-like particles and some small-sized particles (about 10 nm in diameter) were also observed using immunoelectron microscopy.", [["some small-sized particles", "PROBLEM", 37, 63], ["immunoelectron microscopy", "TEST", 115, 140], ["empty capsid", "OBSERVATION", 5, 17], ["like particles", "OBSERVATION_MODIFIER", 18, 32], ["some", "OBSERVATION_MODIFIER", 37, 41], ["small", "OBSERVATION_MODIFIER", 42, 47], ["sized", "OBSERVATION_MODIFIER", 48, 53], ["particles", "OBSERVATION_MODIFIER", 54, 63], ["10 nm", "OBSERVATION_MODIFIER", 71, 76]]], ["Furthermore, the empty capsid-like particles or intermediates induced high levels of FMDV-specific antibodies in guinea pigs following immunization, and neutralizing antibodies were induced in the second week after vaccination.", [["FMDV", "ORGANISM", 85, 89], ["guinea pigs", "ORGANISM", 113, 124], ["FMDV-specific antibodies", "PROTEIN", 85, 109], ["neutralizing antibodies", "PROTEIN", 153, 176], ["FMDV", "SPECIES", 85, 89], ["guinea pigs", "SPECIES", 113, 124], ["FMDV", "SPECIES", 85, 89], ["pigs", "SPECIES", 120, 124], ["the empty capsid-like particles", "PROBLEM", 13, 44], ["high levels of FMDV", "PROBLEM", 70, 89], ["specific antibodies", "TREATMENT", 90, 109], ["guinea pigs", "TREATMENT", 113, 124], ["immunization", "TREATMENT", 135, 147], ["neutralizing antibodies", "PROBLEM", 153, 176], ["vaccination", "TREATMENT", 215, 226], ["high levels", "OBSERVATION_MODIFIER", 70, 81]]], ["These recombinant, non-infectious, FMDV empty capsids are potentially useful for the development of new diagnostic techniques and vaccines.", [["FMDV empty capsids", "ORGANISM", 35, 53], ["FMDV", "SPECIES", 35, 39], ["FMDV", "SPECIES", 35, 39], ["non-infectious", "PROBLEM", 19, 33], ["FMDV empty capsids", "TREATMENT", 35, 53], ["vaccines", "TREATMENT", 130, 138], ["non-infectious", "OBSERVATION_MODIFIER", 19, 33], ["new", "OBSERVATION_MODIFIER", 100, 103]]]], "PMC7204698": [], "PMC7372202": [["Case Scenario 1 ::: IntroductionA 20 year\u2010old male presented to the accident and emergency department with three\u2010week history of increasing stridor in Gandhi medical college, Bhopal.", [["stridor", "DISEASE", 140, 147], ["increasing stridor", "PROBLEM", 129, 147], ["increasing", "OBSERVATION_MODIFIER", 129, 139], ["stridor", "OBSERVATION", 140, 147]]], ["He had history of suicidal attempt 6 months back, following which was on ventilator support for 7 days.", [["suicidal attempt", "PROBLEM", 18, 34], ["ventilator support", "TREATMENT", 73, 91]]], ["There was no history of dysphagia.", [["dysphagia", "DISEASE", 24, 33], ["dysphagia", "PROBLEM", 24, 33], ["no history of", "UNCERTAINTY", 10, 23], ["dysphagia", "OBSERVATION", 24, 33]]], ["There was no evidence of any weight loss in the recent past.", [["weight loss", "DISEASE", 29, 40], ["weight loss", "PROBLEM", 29, 40], ["no evidence of", "UNCERTAINTY", 10, 24], ["weight loss", "OBSERVATION", 29, 40]]], ["Indirect laryngoscopy revealed upper tracheal stenosis with pin hole size lumen(Cotton-Myer:Grade3).", [["tracheal", "ANATOMY", 37, 45], ["lumen", "ANATOMY", 74, 79], ["tracheal stenosis", "DISEASE", 37, 54], ["upper tracheal", "ORGANISM_SUBDIVISION", 31, 45], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 79], ["Indirect laryngoscopy", "TEST", 0, 21], ["upper tracheal stenosis", "PROBLEM", 31, 54], ["pin hole size lumen", "TREATMENT", 60, 79], ["upper", "ANATOMY_MODIFIER", 31, 36], ["tracheal", "ANATOMY", 37, 45], ["stenosis", "OBSERVATION", 46, 54], ["pin hole", "OBSERVATION", 60, 68], ["size", "OBSERVATION_MODIFIER", 69, 73], ["lumen", "OBSERVATION_MODIFIER", 74, 79]]], ["Patient had stridor and respiratory distress with increasing pulse rate and hypoxemia.", [["respiratory", "ANATOMY", 24, 35], ["stridor", "DISEASE", 12, 19], ["respiratory distress", "DISEASE", 24, 44], ["hypoxemia", "DISEASE", 76, 85], ["Patient", "SPECIES", 0, 7], ["stridor", "PROBLEM", 12, 19], ["respiratory distress", "PROBLEM", 24, 44], ["increasing pulse rate", "PROBLEM", 50, 71], ["hypoxemia", "PROBLEM", 76, 85], ["stridor", "OBSERVATION", 12, 19], ["respiratory distress", "OBSERVATION", 24, 44], ["increasing", "OBSERVATION_MODIFIER", 50, 60], ["pulse rate", "OBSERVATION", 61, 71], ["hypoxemia", "OBSERVATION", 76, 85]]], ["Decision for surgical tracheostomy under local anesthesia, avoiding intravenous sedation was taken in view of persisting stridor and impending airway obstruction.", [["intravenous", "ANATOMY", 68, 79], ["airway", "ANATOMY", 143, 149], ["stridor", "DISEASE", 121, 128], ["airway obstruction", "DISEASE", 143, 161], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 79], ["airway obstruction", "PATHOLOGICAL_FORMATION", 143, 161], ["surgical tracheostomy", "TREATMENT", 13, 34], ["local anesthesia", "TREATMENT", 41, 57], ["intravenous sedation", "TREATMENT", 68, 88], ["persisting stridor", "PROBLEM", 110, 128], ["impending airway obstruction", "PROBLEM", 133, 161], ["persisting", "OBSERVATION_MODIFIER", 110, 120], ["stridor", "OBSERVATION", 121, 128], ["airway", "ANATOMY", 143, 149], ["obstruction", "OBSERVATION", 150, 161]]], ["Patient was shifted to operation theater and gave 100% oxygen maintaining spontaneous breathing.", [["oxygen", "CHEMICAL", 55, 61], ["oxygen", "CHEMICAL", 55, 61], ["Patient", "ORGANISM", 0, 7], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["Patient", "SPECIES", 0, 7], ["100% oxygen", "TREATMENT", 50, 61], ["spontaneous breathing", "OBSERVATION", 74, 95]]], ["After proper positioning and local anesthesia infiltration, tracheostomy procedure was started.", [["local anesthesia infiltration", "TREATMENT", 29, 58], ["tracheostomy procedure", "TREATMENT", 60, 82], ["anesthesia infiltration", "OBSERVATION", 35, 58]]], ["Soft tissues were fibrosed, making the tissue planes unappreciable and the tracheal rings were also not able to appreciate.", [["Soft tissues", "ANATOMY", 0, 12], ["tissue", "ANATOMY", 39, 45], ["tracheal rings", "ANATOMY", 75, 89], ["Soft tissues", "TISSUE", 0, 12], ["tissue", "TISSUE", 39, 45], ["tracheal rings", "MULTI-TISSUE_STRUCTURE", 75, 89], ["the tissue planes", "TEST", 35, 52], ["the tracheal rings", "TREATMENT", 71, 89], ["tissues", "ANATOMY", 5, 12], ["fibrosed", "OBSERVATION", 18, 26], ["tracheal rings", "ANATOMY", 75, 89]]], ["Trachea was brought into field with finger sweeping movement following the cricoid ring from above.", [["Trachea", "ANATOMY", 0, 7], ["finger", "ANATOMY", 36, 42], ["cricoid ring", "ANATOMY", 75, 87], ["finger", "ORGANISM_SUBDIVISION", 36, 42], ["cricoid ring", "MULTI-TISSUE_STRUCTURE", 75, 87], ["the cricoid ring", "TREATMENT", 71, 87], ["finger", "ANATOMY", 36, 42], ["sweeping movement", "OBSERVATION", 43, 60], ["cricoid ring", "OBSERVATION", 75, 87]]], ["Trachea was cord like, hardly the thickness of pencil with soft to firm consistency.", [["Trachea", "ANATOMY", 0, 7], ["cord", "ANATOMY", 12, 16], ["Trachea", "MULTI-TISSUE_STRUCTURE", 0, 7], ["cord", "ORGAN", 12, 16], ["cord", "ANATOMY", 12, 16], ["soft to firm", "OBSERVATION_MODIFIER", 59, 71]]], ["Meanwhile, mask ventilation with spontaneous ventilation was becoming increasingly difficult.", [["mask ventilation", "TREATMENT", 11, 27], ["spontaneous ventilation", "TREATMENT", 33, 56], ["mask ventilation", "OBSERVATION", 11, 27]]], ["Trachea confirmed with air aspiration and small opening was made with 11 no blade.", [["Trachea", "ANATOMY", 0, 7], ["Trachea", "DISEASE", 0, 7], ["air aspiration", "PROBLEM", 23, 37], ["small opening", "PROBLEM", 42, 55], ["air aspiration", "OBSERVATION", 23, 37], ["small", "OBSERVATION_MODIFIER", 42, 47], ["opening", "OBSERVATION", 48, 55]]], ["5 mm Endotracheal tube was passed with difficulty.", [["Endotracheal tube", "ANATOMY", 5, 22], ["tube", "TISSUE", 18, 22], ["Endotracheal tube", "TREATMENT", 5, 22], ["Endotracheal tube", "OBSERVATION", 5, 22]]], ["After 5minutes, 7.5 mm internal diameter (ID) tracheostomy tube inserted removing the ETT.", [["7.5 mm internal diameter (ID) tracheostomy tube", "TREATMENT", 16, 63], ["the ETT", "TREATMENT", 82, 89], ["7.5 mm", "OBSERVATION_MODIFIER", 16, 22], ["internal", "OBSERVATION_MODIFIER", 23, 31], ["diameter", "OBSERVATION_MODIFIER", 32, 40], ["tracheostomy tube", "OBSERVATION", 46, 63], ["ETT", "OBSERVATION", 86, 89]]], ["CT done postoperatively revealed invisible lumen in the upper trachea and patient was referred to higher centre for further management.", [["lumen", "ANATOMY", 43, 48], ["upper trachea", "ANATOMY", 56, 69], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 48], ["upper trachea", "ORGAN", 56, 69], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["CT", "TEST", 0, 2], ["invisible lumen in the upper trachea", "PROBLEM", 33, 69], ["further management", "TREATMENT", 116, 134], ["invisible lumen", "OBSERVATION", 33, 48], ["upper", "ANATOMY_MODIFIER", 56, 61], ["trachea", "ANATOMY", 62, 69]]], ["Throughout the event, patient maintained oxygen saturation levels above 90%.", [["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 41, 47], ["patient", "ORGANISM", 22, 29], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["patient", "SPECIES", 22, 29], ["oxygen saturation levels", "TEST", 41, 65]]], ["Retrograde intubation device and flexible fiber-optic intubation was not possible.", [["Retrograde intubation device", "TREATMENT", 0, 28], ["flexible fiber-optic intubation", "TREATMENT", 33, 64], ["intubation", "OBSERVATION", 11, 21], ["optic intubation", "OBSERVATION", 48, 64], ["not possible", "UNCERTAINTY", 69, 81]]], ["Emergency cricothyrodotomy was not feasible since constriction was at the level of cricoid.Case Scenario 2 ::: IntroductionSixty-eight years old female presented to the emergency department with dysphagia, stridor of 2 weeks duration along with respiratory distress.", [["cricoid", "ANATOMY", 83, 90], ["respiratory", "ANATOMY", 245, 256], ["dysphagia", "DISEASE", 195, 204], ["stridor", "DISEASE", 206, 213], ["respiratory distress", "DISEASE", 245, 265], ["cricoid", "MULTI-TISSUE_STRUCTURE", 83, 90], ["female", "ORGANISM", 145, 151], ["Emergency cricothyrodotomy", "TREATMENT", 0, 26], ["constriction", "PROBLEM", 50, 62], ["dysphagia", "PROBLEM", 195, 204], ["stridor of 2 weeks duration", "PROBLEM", 206, 233], ["respiratory distress", "PROBLEM", 245, 265], ["constriction", "OBSERVATION", 50, 62], ["cricoid", "ANATOMY", 83, 90], ["dysphagia", "OBSERVATION", 195, 204], ["stridor", "OBSERVATION", 206, 213], ["respiratory", "ANATOMY", 245, 256], ["distress", "OBSERVATION", 257, 265]]], ["She had excessive expectoration since 2 weeks.", [["expectoration", "DISEASE", 18, 31], ["excessive expectoration", "PROBLEM", 8, 31], ["excessive", "OBSERVATION_MODIFIER", 8, 17], ["expectoration", "OBSERVATION", 18, 31]]], ["She was obese with short neck and had right sided pulmonary crepitation on auscultation.", [["neck", "ANATOMY", 25, 29], ["pulmonary", "ANATOMY", 50, 59], ["neck", "ORGANISM_SUBDIVISION", 25, 29], ["pulmonary", "ORGAN", 50, 59], ["obese", "PROBLEM", 8, 13], ["short neck", "PROBLEM", 19, 29], ["right sided pulmonary crepitation", "PROBLEM", 38, 71], ["auscultation", "TEST", 75, 87], ["obese", "OBSERVATION", 8, 13], ["right", "ANATOMY_MODIFIER", 38, 43], ["sided", "ANATOMY_MODIFIER", 44, 49], ["pulmonary", "ANATOMY", 50, 59], ["crepitation", "OBSERVATION", 60, 71], ["auscultation", "OBSERVATION", 75, 87]]], ["Indirect laryngoscopy showed oropharyngeal malignancy with supraglottic extension.", [["oropharyngeal malignancy", "ANATOMY", 29, 53], ["supraglottic", "ANATOMY", 59, 71], ["malignancy", "DISEASE", 43, 53], ["oropharyngeal malignancy", "CANCER", 29, 53], ["Indirect laryngoscopy", "TEST", 0, 21], ["oropharyngeal malignancy", "PROBLEM", 29, 53], ["supraglottic extension", "PROBLEM", 59, 81], ["oropharyngeal", "ANATOMY", 29, 42], ["malignancy", "OBSERVATION", 43, 53], ["supraglottic", "ANATOMY", 59, 71]]], ["Patient was taken for surgical tracheostomy in OT under local anaesthesia.", [["Patient", "SPECIES", 0, 7], ["surgical tracheostomy", "TREATMENT", 22, 43], ["local anaesthesia", "TREATMENT", 56, 73], ["tracheostomy", "OBSERVATION", 31, 43]]], ["Difficult tracheostomy was anticipated in view of short neck.", [["neck", "ANATOMY", 56, 60], ["neck", "ORGANISM_SUBDIVISION", 56, 60], ["Difficult tracheostomy", "TREATMENT", 0, 22], ["short neck", "PROBLEM", 50, 60], ["tracheostomy", "OBSERVATION", 10, 22], ["neck", "ANATOMY", 56, 60]]], ["But the tracheostomy was uneventful even though only small portion of cervical trachea was seen just above the suprasternal area and 7.5 mm ID tracheostomy tube insertion done.Case Scenario 3 ::: IntroductionSeventeen years old male presented to the emergency department with history of sustained blunt trauma to neck in road traffic accident 8 h after injury.", [["cervical trachea", "ANATOMY", 70, 86], ["suprasternal area", "ANATOMY", 111, 128], ["neck", "ANATOMY", 313, 317], ["trauma", "DISEASE", 303, 309], ["cervical trachea", "MULTI-TISSUE_STRUCTURE", 70, 86], ["neck", "ORGANISM_SUBDIVISION", 313, 317], ["the tracheostomy", "TREATMENT", 4, 20], ["small portion of cervical trachea", "PROBLEM", 53, 86], ["7.5 mm ID tracheostomy tube insertion", "TREATMENT", 133, 170], ["sustained blunt trauma to neck", "PROBLEM", 287, 317], ["injury", "PROBLEM", 353, 359], ["tracheostomy", "OBSERVATION", 8, 20], ["small", "OBSERVATION_MODIFIER", 53, 58], ["portion", "OBSERVATION_MODIFIER", 59, 66], ["cervical trachea", "ANATOMY", 70, 86], ["suprasternal", "ANATOMY", 111, 123], ["area", "ANATOMY_MODIFIER", 124, 128], ["7.5 mm", "OBSERVATION", 133, 139], ["tracheostomy tube", "OBSERVATION", 143, 160], ["insertion", "OBSERVATION", 161, 170], ["blunt trauma", "OBSERVATION", 297, 309], ["neck", "ANATOMY", 313, 317]]], ["He was brought with stridor and increasing respiratory distress.", [["respiratory", "ANATOMY", 43, 54], ["stridor", "DISEASE", 20, 27], ["respiratory distress", "DISEASE", 43, 63], ["He", "ORGANISM", 0, 2], ["stridor", "PROBLEM", 20, 27], ["increasing respiratory distress", "PROBLEM", 32, 63], ["stridor", "OBSERVATION", 20, 27], ["increasing", "OBSERVATION_MODIFIER", 32, 42], ["respiratory distress", "OBSERVATION", 43, 63]]], ["On examination, surgical emphysema (Fig. 1), was present superiorly upto lower border of mandible and inferiorly upto upper chest along with localised bruising and tenderness.", [["lower border", "ANATOMY", 73, 85], ["mandible", "ANATOMY", 89, 97], ["upper chest", "ANATOMY", 118, 129], ["emphysema", "DISEASE", 25, 34], ["bruising", "DISEASE", 151, 159], ["tenderness", "DISEASE", 164, 174], ["mandible", "ORGAN", 89, 97], ["upper chest", "ORGANISM_SUBDIVISION", 118, 129], ["examination", "TEST", 3, 14], ["surgical emphysema", "PROBLEM", 16, 34], ["localised bruising", "PROBLEM", 141, 159], ["tenderness", "PROBLEM", 164, 174], ["surgical", "OBSERVATION_MODIFIER", 16, 24], ["emphysema", "OBSERVATION", 25, 34], ["superiorly", "ANATOMY_MODIFIER", 57, 67], ["lower", "ANATOMY_MODIFIER", 73, 78], ["border", "ANATOMY_MODIFIER", 79, 85], ["mandible", "ANATOMY", 89, 97], ["inferiorly", "ANATOMY_MODIFIER", 102, 112], ["upper", "ANATOMY_MODIFIER", 118, 123], ["chest", "ANATOMY", 124, 129], ["localised", "OBSERVATION_MODIFIER", 141, 150], ["bruising", "OBSERVATION", 151, 159], ["tenderness", "OBSERVATION", 164, 174]]], ["Endotracheal intubation was not tried inview of creation of false passage in case of laryngotracheal laceration.", [["Endotracheal", "ANATOMY", 0, 12], ["laryngotracheal", "ANATOMY", 85, 100], ["laryngotracheal laceration", "DISEASE", 85, 111], ["laryngotracheal", "ORGAN", 85, 100], ["Endotracheal intubation", "TREATMENT", 0, 23], ["false passage", "PROBLEM", 60, 73], ["laryngotracheal laceration", "PROBLEM", 85, 111], ["intubation", "OBSERVATION", 13, 23], ["false passage", "OBSERVATION", 60, 73], ["laryngotracheal", "ANATOMY", 85, 100], ["laceration", "OBSERVATION", 101, 111]]], ["Tracheostomy was performed under local anaesthesia and the only difficulty was the depth of the plane of trachea due to increased skin tracheal distance due to surgical emphysema.", [["trachea", "ANATOMY", 105, 112], ["skin tracheal", "ANATOMY", 130, 143], ["emphysema", "DISEASE", 169, 178], ["trachea", "ORGAN", 105, 112], ["skin tracheal", "MULTI-TISSUE_STRUCTURE", 130, 143], ["emphysema", "PATHOLOGICAL_FORMATION", 169, 178], ["Tracheostomy", "TREATMENT", 0, 12], ["local anaesthesia", "TREATMENT", 33, 50], ["increased skin tracheal distance", "PROBLEM", 120, 152], ["surgical emphysema", "PROBLEM", 160, 178], ["trachea", "ANATOMY", 105, 112], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["skin", "ANATOMY", 130, 134], ["tracheal distance", "OBSERVATION", 135, 152], ["surgical", "OBSERVATION_MODIFIER", 160, 168], ["emphysema", "OBSERVATION", 169, 178]]], ["He was conservatively managed with successful decannulation after 2 weeks.Case Scenario 4 ::: IntroductionA 65 year old female presented with complaints of oral cavity and neck pain and difficulty in swallowing for 10 days.", [["oral cavity", "ANATOMY", 156, 167], ["neck", "ANATOMY", 172, 176], ["neck pain", "DISEASE", 172, 181], ["female", "ORGANISM", 120, 126], ["oral cavity", "ORGANISM_SUBDIVISION", 156, 167], ["neck", "ORGANISM_SUBDIVISION", 172, 176], ["successful decannulation", "TREATMENT", 35, 59], ["oral cavity", "PROBLEM", 156, 167], ["neck pain", "PROBLEM", 172, 181], ["difficulty in swallowing", "PROBLEM", 186, 210], ["oral cavity", "ANATOMY", 156, 167], ["neck", "ANATOMY", 172, 176], ["pain", "OBSERVATION", 177, 181]]], ["She reported with progressive swelling in the neck and inability to open her mouth for which she was conservatively treated in local hospital.", [["neck", "ANATOMY", 46, 50], ["mouth", "ANATOMY", 77, 82], ["swelling", "DISEASE", 30, 38], ["neck", "ORGAN", 46, 50], ["mouth", "ORGANISM_SUBDIVISION", 77, 82], ["progressive swelling in the neck", "PROBLEM", 18, 50], ["progressive", "OBSERVATION_MODIFIER", 18, 29], ["swelling", "OBSERVATION", 30, 38], ["neck", "ANATOMY", 46, 50], ["mouth", "ANATOMY", 77, 82]]], ["An infected third molar had been extracted 2 weeks before the present illness.", [["third molar", "ANATOMY", 12, 23], ["An infected third molar", "PROBLEM", 0, 23], ["infected", "OBSERVATION_MODIFIER", 3, 11], ["third", "OBSERVATION_MODIFIER", 12, 17], ["molar", "OBSERVATION", 18, 23]]], ["Her mouth opening was two fingerbreadth with limited neck flexion and extension.", [["mouth", "ANATOMY", 4, 9], ["neck", "ANATOMY", 53, 57], ["mouth", "ORGANISM_SUBDIVISION", 4, 9], ["neck", "ORGANISM_SUBDIVISION", 53, 57], ["mouth", "ANATOMY", 4, 9], ["neck flexion", "ANATOMY", 53, 65]]], ["She was diagnosed to have Ludwig\u2019s angina and underwent incision and drainage.", [["Ludwig\u2019s angina", "DISEASE", 26, 41], ["angina", "PROBLEM", 35, 41], ["incision", "TREATMENT", 56, 64], ["drainage", "TREATMENT", 69, 77], ["incision", "OBSERVATION", 56, 64], ["drainage", "OBSERVATION", 69, 77]]], ["Meanwhile she also diagnosed to have diabetes mellitus.", [["diabetes mellitus", "DISEASE", 37, 54], ["diabetes mellitus", "PROBLEM", 37, 54], ["diabetes", "OBSERVATION", 37, 45]]], ["Irrespective of the antibiotic in accordance with culture sensitivity, the infection spreaded to deep neck spaces including bilateral parapharyngeal, paratracheal spaces which were also drained.", [["neck", "ANATOMY", 102, 106], ["parapharyngeal", "ANATOMY", 134, 148], ["paratracheal spaces", "ANATOMY", 150, 169], ["infection", "DISEASE", 75, 84], ["neck", "ORGAN", 102, 106], ["parapharyngeal", "ORGAN", 134, 148], ["the antibiotic", "TREATMENT", 16, 30], ["culture sensitivity", "TEST", 50, 69], ["the infection", "PROBLEM", 71, 84], ["bilateral parapharyngeal, paratracheal spaces", "PROBLEM", 124, 169], ["infection", "OBSERVATION", 75, 84], ["deep", "ANATOMY_MODIFIER", 97, 101], ["neck", "ANATOMY", 102, 106], ["bilateral", "ANATOMY_MODIFIER", 124, 133], ["parapharyngeal", "ANATOMY", 134, 148], ["paratracheal", "ANATOMY", 150, 162], ["drained", "OBSERVATION", 186, 193]]], ["She developed stridor and xray lateral view of neck showed oedematous epiglottis, with laryngeal lumen narrowing.", [["neck", "ANATOMY", 47, 51], ["oedematous epiglottis", "ANATOMY", 59, 80], ["laryngeal lumen", "ANATOMY", 87, 102], ["stridor", "DISEASE", 14, 21], ["oedematous epiglottis", "DISEASE", 59, 80], ["neck", "ORGANISM_SUBDIVISION", 47, 51], ["epiglottis", "ORGAN", 70, 80], ["laryngeal lumen", "MULTI-TISSUE_STRUCTURE", 87, 102], ["stridor", "PROBLEM", 14, 21], ["xray lateral view of neck", "TEST", 26, 51], ["oedematous epiglottis", "PROBLEM", 59, 80], ["laryngeal lumen narrowing", "PROBLEM", 87, 112], ["stridor", "OBSERVATION", 14, 21], ["neck", "ANATOMY", 47, 51], ["oedematous epiglottis", "ANATOMY", 59, 80], ["laryngeal", "ANATOMY", 87, 96], ["lumen", "ANATOMY_MODIFIER", 97, 102], ["narrowing", "OBSERVATION", 103, 112]]], ["Patient was taken for trachestomy in view of safe airway and prevention against aspiration.", [["airway", "ANATOMY", 50, 56], ["airway", "MULTI-TISSUE_STRUCTURE", 50, 56], ["Patient", "SPECIES", 0, 7], ["trachestomy", "TREATMENT", 22, 33], ["safe airway", "TREATMENT", 45, 56], ["aspiration", "PROBLEM", 80, 90], ["airway", "ANATOMY", 50, 56], ["aspiration", "OBSERVATION", 80, 90]]], ["She was positioned and local infiltration given.", [["local infiltration", "TREATMENT", 23, 41], ["local", "OBSERVATION_MODIFIER", 23, 28], ["infiltration", "OBSERVATION", 29, 41]]], ["As dissection began, surgical planes were found to be fibrosed and leaky from the pus collection pockets on either sides of trachea.", [["pus", "ANATOMY", 82, 85], ["trachea", "ANATOMY", 124, 131], ["trachea", "MULTI-TISSUE_STRUCTURE", 124, 131], ["dissection", "PROBLEM", 3, 13], ["surgical planes", "TREATMENT", 21, 36], ["fibrosed", "PROBLEM", 54, 62], ["leaky from the pus collection pockets", "PROBLEM", 67, 104], ["dissection", "OBSERVATION", 3, 13], ["leaky", "OBSERVATION", 67, 72], ["pus", "OBSERVATION", 82, 85], ["pockets", "OBSERVATION_MODIFIER", 97, 104], ["trachea", "ANATOMY", 124, 131]]], ["Trachea was also fibrosed and tethered to surrounding tissue.", [["Trachea", "ANATOMY", 0, 7], ["tissue", "ANATOMY", 54, 60], ["tissue", "TISSUE", 54, 60], ["fibrosed", "OBSERVATION", 17, 25]]], ["7.5 mm ID tracheostomy tube inserted and connected to airway circuit.", [["tube", "ANATOMY", 23, 27], ["airway", "ANATOMY", 54, 60], ["airway", "MULTI-TISSUE_STRUCTURE", 54, 60], ["7.5 mm ID tracheostomy tube", "TREATMENT", 0, 27], ["airway circuit", "TREATMENT", 54, 68], ["tracheostomy tube", "OBSERVATION", 10, 27], ["airway circuit", "OBSERVATION", 54, 68]]], ["Following which retropharyngeal abscess was drained under surface anaesthesia with lignocaine spray with head low position.Case Scenario 5 ::: IntroductionA 14 month old boy admitted in PICU with three-day history of fever and sore throat with progressive difficulty in swallowing and breathing.", [["retropharyngeal abscess", "ANATOMY", 16, 39], ["surface", "ANATOMY", 58, 65], ["head", "ANATOMY", 105, 109], ["abscess", "DISEASE", 32, 39], ["lignocaine", "CHEMICAL", 83, 93], ["fever", "DISEASE", 217, 222], ["sore throat", "DISEASE", 227, 238], ["difficulty in swallowing and breathing", "DISEASE", 256, 294], ["lignocaine", "CHEMICAL", 83, 93], ["retropharyngeal abscess", "PATHOLOGICAL_FORMATION", 16, 39], ["lignocaine", "SIMPLE_CHEMICAL", 83, 93], ["head", "ORGANISM_SUBDIVISION", 105, 109], ["boy", "ORGANISM", 170, 173], ["boy", "SPECIES", 170, 173], ["retropharyngeal abscess", "PROBLEM", 16, 39], ["surface anaesthesia", "TREATMENT", 58, 77], ["lignocaine spray", "TREATMENT", 83, 99], ["head low position", "TREATMENT", 105, 122], ["fever", "PROBLEM", 217, 222], ["sore throat", "PROBLEM", 227, 238], ["progressive difficulty in swallowing", "PROBLEM", 244, 280], ["retropharyngeal", "ANATOMY", 16, 31], ["abscess", "OBSERVATION", 32, 39], ["drained", "OBSERVATION", 44, 51], ["head", "ANATOMY", 105, 109], ["low position", "OBSERVATION", 110, 122], ["fever", "OBSERVATION", 217, 222], ["sore throat", "ANATOMY", 227, 238], ["progressive", "OBSERVATION_MODIFIER", 244, 255], ["difficulty", "OBSERVATION", 256, 266]]], ["Clinically, the child was severely ill; with stridor and respiratory distress.", [["respiratory", "ANATOMY", 57, 68], ["ill", "DISEASE", 35, 38], ["stridor", "DISEASE", 45, 52], ["respiratory distress", "DISEASE", 57, 77], ["child", "ORGANISM", 16, 21], ["child", "SPECIES", 16, 21], ["severely ill", "PROBLEM", 26, 38], ["stridor", "PROBLEM", 45, 52], ["respiratory distress", "PROBLEM", 57, 77], ["stridor", "OBSERVATION", 45, 52], ["respiratory distress", "OBSERVATION", 57, 77]]], ["On oropharyngeal examination, a whitish membrane covering the uvula, tonsils and posterior pharyngeal wall was noted.", [["oropharyngeal", "ANATOMY", 3, 16], ["whitish membrane", "ANATOMY", 32, 48], ["uvula", "ANATOMY", 62, 67], ["tonsils", "ANATOMY", 69, 76], ["posterior pharyngeal wall", "ANATOMY", 81, 106], ["oropharyngeal", "ORGANISM_SUBDIVISION", 3, 16], ["whitish membrane", "MULTI-TISSUE_STRUCTURE", 32, 48], ["uvula", "ORGAN", 62, 67], ["tonsils", "ORGAN", 69, 76], ["posterior pharyngeal wall", "MULTI-TISSUE_STRUCTURE", 81, 106], ["oropharyngeal examination", "TEST", 3, 28], ["a whitish membrane covering the uvula, tonsils and posterior pharyngeal wall", "PROBLEM", 30, 106], ["oropharyngeal", "ANATOMY", 3, 16], ["uvula", "ANATOMY", 62, 67], ["tonsils", "ANATOMY", 69, 76], ["posterior", "ANATOMY_MODIFIER", 81, 90], ["pharyngeal wall", "ANATOMY", 91, 106]]], ["But he had no bull neck.", [["bull neck", "ANATOMY", 14, 23], ["neck", "ORGANISM_SUBDIVISION", 19, 23], ["bull neck", "PROBLEM", 14, 23], ["neck", "ANATOMY", 19, 23]]], ["A sample of the pseudomembrane and a tonsillar swab were collected and submitted to the bacteriology laboratory for routine microscopy and culture, as well as culture on selective media for Corynebacterium diphtheria (Fig. 2).", [["sample", "ANATOMY", 2, 8], ["pseudomembrane", "ANATOMY", 16, 30], ["tonsillar swab", "ANATOMY", 37, 51], ["Corynebacterium diphtheria", "DISEASE", 190, 216], ["pseudomembrane", "CANCER", 16, 30], ["tonsillar swab", "CANCER", 37, 51], ["Corynebacterium diphtheria", "ORGANISM", 190, 216], ["Corynebacterium diphtheria", "SPECIES", 190, 216], ["Corynebacterium diphtheria", "SPECIES", 190, 216], ["A sample of the pseudomembrane", "TEST", 0, 30], ["a tonsillar swab", "TEST", 35, 51], ["routine microscopy", "TEST", 116, 134], ["culture", "TEST", 139, 146], ["culture", "TEST", 159, 166], ["selective media", "TREATMENT", 170, 185], ["Corynebacterium diphtheria", "PROBLEM", 190, 216], ["tonsillar", "ANATOMY", 37, 46]]], ["An emergency tracheostomy was performed, and 3 mm (ID) ETT was inserted with adequate stabilisation as tracheostomy tube was unavailable and following which the child was transferred to the intensive care unit for further management.DiscussionRapid development of severe hypoxemia, particularly associated with bradycardia, is an indication for imminent intervention with an invasive technique.", [["hypoxemia", "DISEASE", 271, 280], ["bradycardia", "DISEASE", 311, 322], ["child", "ORGANISM", 161, 166], ["An emergency tracheostomy", "TREATMENT", 0, 25], ["3 mm (ID) ETT", "TREATMENT", 45, 58], ["adequate stabilisation", "TREATMENT", 77, 99], ["tracheostomy tube", "TREATMENT", 103, 120], ["further management", "TREATMENT", 214, 232], ["severe hypoxemia", "PROBLEM", 264, 280], ["bradycardia", "PROBLEM", 311, 322], ["imminent intervention", "TREATMENT", 345, 366], ["an invasive technique", "TREATMENT", 372, 393], ["tracheostomy", "OBSERVATION", 13, 25], ["tracheostomy tube", "OBSERVATION", 103, 120], ["severe", "OBSERVATION_MODIFIER", 264, 270], ["hypoxemia", "OBSERVATION", 271, 280]]], ["Rapid reoxygenation is now necessary, and this is best achieved with a combination of an invasive airway device and a ventilation technique which is capable of reliably delivering a large minute volume with an FiO2 of 1.0.", [["airway", "ANATOMY", 98, 104], ["airway", "MULTI-TISSUE_STRUCTURE", 98, 104], ["Rapid reoxygenation", "PROBLEM", 0, 19], ["an invasive airway device", "TREATMENT", 86, 111], ["a ventilation technique", "TREATMENT", 116, 139], ["a large minute volume", "TREATMENT", 180, 201], ["an FiO2", "TEST", 207, 214], ["reoxygenation", "OBSERVATION", 6, 19], ["invasive airway device", "OBSERVATION", 89, 111], ["large", "OBSERVATION_MODIFIER", 182, 187]]], ["Many cricothyroidotomy techniques have been criticised because they are not capable of providing effective ventilation [6].", [["Many cricothyroidotomy techniques", "TREATMENT", 0, 33], ["cricothyroidotomy", "OBSERVATION", 5, 22]]], ["Classical emergency surgical tracheostomy involves incision through skin and platysma, division of the isthmus of the thyroid gland, haemostasis, incision of tracheal cartilage, and insertion of a cuffed tracheostomy tube.", [["skin", "ANATOMY", 68, 72], ["platysma", "ANATOMY", 77, 85], ["isthmus", "ANATOMY", 103, 110], ["thyroid gland", "ANATOMY", 118, 131], ["tracheal cartilage", "ANATOMY", 158, 176], ["haemostasis", "DISEASE", 133, 144], ["skin", "ORGAN", 68, 72], ["platysma", "ORGAN", 77, 85], ["isthmus", "MULTI-TISSUE_STRUCTURE", 103, 110], ["thyroid gland", "ORGAN", 118, 131], ["tracheal cartilage", "TISSUE", 158, 176], ["Classical emergency surgical tracheostomy", "TREATMENT", 0, 41], ["incision through skin and platysma", "PROBLEM", 51, 85], ["incision of tracheal cartilage", "TREATMENT", 146, 176], ["a cuffed tracheostomy tube", "TREATMENT", 195, 221], ["surgical tracheostomy", "OBSERVATION", 20, 41], ["incision", "OBSERVATION", 51, 59], ["skin", "ANATOMY", 68, 72], ["platysma", "ANATOMY", 77, 85], ["isthmus", "ANATOMY_MODIFIER", 103, 110], ["thyroid gland", "ANATOMY", 118, 131], ["haemostasis", "OBSERVATION", 133, 144], ["incision", "OBSERVATION_MODIFIER", 146, 154], ["tracheal cartilage", "ANATOMY", 158, 176], ["insertion", "OBSERVATION_MODIFIER", 182, 191], ["cuffed", "OBSERVATION_MODIFIER", 197, 203], ["tracheostomy tube", "OBSERVATION", 204, 221]]], ["Although tracheostomies are commonly performed in critically ill patients, the reported complication rates following insertion of tracheostomy vary widely, from as low as 2.1% to as high as 20% [7].", [["critically ill", "DISEASE", 50, 64], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["tracheostomies", "TREATMENT", 9, 23], ["the reported complication rates", "PROBLEM", 75, 106], ["insertion of tracheostomy", "TREATMENT", 117, 142], ["tracheostomies", "OBSERVATION", 9, 23], ["tracheostomy", "OBSERVATION", 130, 142]]], ["The rate of major or serious insertion complications like major bleeding, posterior tracheal wall injury, pneumothorax, and death is approximately 6% [8].", [["posterior tracheal wall", "ANATOMY", 74, 97], ["bleeding", "DISEASE", 64, 72], ["tracheal wall injury", "DISEASE", 84, 104], ["pneumothorax", "DISEASE", 106, 118], ["death", "DISEASE", 124, 129], ["tracheal wall", "MULTI-TISSUE_STRUCTURE", 84, 97], ["major or serious insertion complications", "PROBLEM", 12, 52], ["major bleeding", "PROBLEM", 58, 72], ["posterior tracheal wall injury", "PROBLEM", 74, 104], ["pneumothorax", "PROBLEM", 106, 118], ["death", "PROBLEM", 124, 129], ["major", "OBSERVATION_MODIFIER", 12, 17], ["serious", "OBSERVATION_MODIFIER", 21, 28], ["major", "OBSERVATION_MODIFIER", 58, 63], ["bleeding", "OBSERVATION", 64, 72], ["posterior", "ANATOMY_MODIFIER", 74, 83], ["tracheal", "ANATOMY", 84, 92], ["wall", "ANATOMY_MODIFIER", 93, 97], ["injury", "OBSERVATION", 98, 104], ["pneumothorax", "OBSERVATION", 106, 118]]], ["Pneumothorax and subcutaneous emphysema following tracheostomy has been reported to occur in 2 to 5% of cases [9].", [["subcutaneous emphysema", "ANATOMY", 17, 39], ["Pneumothorax", "DISEASE", 0, 12], ["emphysema", "DISEASE", 30, 39], ["Pneumothorax", "PROBLEM", 0, 12], ["subcutaneous emphysema", "PROBLEM", 17, 39], ["tracheostomy", "TREATMENT", 50, 62], ["subcutaneous", "ANATOMY", 17, 29], ["emphysema", "OBSERVATION", 30, 39], ["tracheostomy", "OBSERVATION", 50, 62]]], ["In upper tracheal stenosis, the lower limit of tracheal narrowing cannot be made without imaging and evenif there is no anatomical stenosis, the functional stenosis due to collapse of trachea with Bernoulli\u2019s effect, have to be anticipated.", [["upper tracheal", "ANATOMY", 3, 17], ["tracheal", "ANATOMY", 47, 55], ["trachea", "ANATOMY", 184, 191], ["tracheal stenosis", "DISEASE", 9, 26], ["stenosis", "DISEASE", 131, 139], ["stenosis", "DISEASE", 156, 164], ["upper tracheal", "MULTI-TISSUE_STRUCTURE", 3, 17], ["tracheal", "MULTI-TISSUE_STRUCTURE", 47, 55], ["trachea", "MULTI-TISSUE_STRUCTURE", 184, 191], ["upper tracheal stenosis", "PROBLEM", 3, 26], ["tracheal narrowing", "PROBLEM", 47, 65], ["imaging", "TEST", 89, 96], ["anatomical stenosis", "PROBLEM", 120, 139], ["the functional stenosis", "PROBLEM", 141, 164], ["collapse of trachea", "PROBLEM", 172, 191], ["Bernoulli\u2019s effect", "PROBLEM", 197, 215], ["upper", "ANATOMY_MODIFIER", 3, 8], ["tracheal", "ANATOMY", 9, 17], ["stenosis", "OBSERVATION", 18, 26], ["lower", "ANATOMY_MODIFIER", 32, 37], ["tracheal", "ANATOMY", 47, 55], ["narrowing", "OBSERVATION", 56, 65], ["no", "UNCERTAINTY", 117, 119], ["anatomical", "OBSERVATION_MODIFIER", 120, 130], ["stenosis", "OBSERVATION", 131, 139], ["functional", "OBSERVATION_MODIFIER", 145, 155], ["stenosis", "OBSERVATION", 156, 164], ["collapse", "OBSERVATION", 172, 180], ["trachea", "ANATOMY", 184, 191], ["Bernoulli\u2019s", "OBSERVATION", 197, 208]]], ["Loss of Anatomical plane due to prior injury to soft tissue and trachea made the situation more worse in case 1.DiscussionMorbid obesity makes the tracheostomy insertions difficult because of their increased skin to tracheal distance.", [["soft tissue", "ANATOMY", 48, 59], ["trachea", "ANATOMY", 64, 71], ["skin", "ANATOMY", 208, 212], ["tracheal", "ANATOMY", 216, 224], ["obesity", "DISEASE", 129, 136], ["soft tissue", "TISSUE", 48, 59], ["trachea", "ORGAN", 64, 71], ["skin", "ORGAN", 208, 212], ["tracheal", "ORGAN", 216, 224], ["Loss of Anatomical plane", "PROBLEM", 0, 24], ["prior injury to soft tissue and trachea", "PROBLEM", 32, 71], ["DiscussionMorbid obesity", "PROBLEM", 112, 136], ["the tracheostomy insertions", "TREATMENT", 143, 170], ["their increased skin to tracheal distance", "PROBLEM", 192, 233], ["Anatomical plane", "OBSERVATION", 8, 24], ["injury", "OBSERVATION", 38, 44], ["soft tissue", "ANATOMY", 48, 59], ["trachea", "ANATOMY", 64, 71], ["tracheostomy insertions", "OBSERVATION", 147, 170], ["increased", "OBSERVATION_MODIFIER", 198, 207], ["skin", "ANATOMY", 208, 212], ["tracheal", "ANATOMY", 216, 224], ["distance", "ANATOMY_MODIFIER", 225, 233]]], ["Short neck adds to the perplexity which is seen in case 2.", [["neck", "ANATOMY", 6, 10], ["neck", "ORGAN", 6, 10], ["Short neck adds to the perplexity", "PROBLEM", 0, 33]]], ["To perform a surgical tracheostomy, the patient's shoulders are elevated and the head is extended unless contraindicated by cervical disease or injury.", [["shoulders", "ANATOMY", 50, 59], ["head", "ANATOMY", 81, 85], ["cervical", "ANATOMY", 124, 132], ["cervical disease", "DISEASE", 124, 140], ["patient", "ORGANISM", 40, 47], ["shoulders", "ORGANISM_SUBDIVISION", 50, 59], ["head", "ORGAN", 81, 85], ["cervical", "ORGAN", 124, 132], ["patient", "SPECIES", 40, 47], ["a surgical tracheostomy", "TREATMENT", 11, 34], ["elevated", "PROBLEM", 64, 72], ["cervical disease", "PROBLEM", 124, 140], ["injury", "PROBLEM", 144, 150], ["surgical tracheostomy", "OBSERVATION", 13, 34], ["shoulders", "ANATOMY", 50, 59], ["elevated", "OBSERVATION", 64, 72], ["head", "ANATOMY", 81, 85], ["cervical", "ANATOMY", 124, 132], ["disease", "OBSERVATION", 133, 140], ["injury", "OBSERVATION", 144, 150]]], ["This position elevates the larynx and exposures more of the upper trachea.", [["larynx", "ANATOMY", 27, 33], ["upper trachea", "ANATOMY", 60, 73], ["larynx", "ORGAN", 27, 33], ["upper trachea", "ORGAN", 60, 73], ["larynx", "ANATOMY", 27, 33], ["upper", "ANATOMY_MODIFIER", 60, 65], ["trachea", "ANATOMY", 66, 73]]], ["However, even in this position, our patient's neck was still too short.", [["neck", "ANATOMY", 46, 50], ["patient", "ORGANISM", 36, 43], ["neck", "ORGAN", 46, 50], ["patient", "SPECIES", 36, 43], ["neck", "ANATOMY", 46, 50]]], ["Muhammad and colleagues [10] compared MRI scans of patients with short, thick necks and those with normal necks.", [["necks", "ANATOMY", 78, 83], ["necks", "ANATOMY", 106, 111], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["MRI scans", "TEST", 38, 47], ["short, thick necks and those with normal necks", "PROBLEM", 65, 111], ["normal", "OBSERVATION", 99, 105], ["necks", "ANATOMY", 106, 111]]], ["They reported that the more exaggerated the curvature of the spine, the further away the trachea is from the skin, and that the trachea follows the curvature of the spine, not the skin.", [["spine", "ANATOMY", 61, 66], ["trachea", "ANATOMY", 89, 96], ["skin", "ANATOMY", 109, 113], ["trachea", "ANATOMY", 128, 135], ["spine", "ANATOMY", 165, 170], ["skin", "ANATOMY", 180, 184], ["spine", "ORGAN", 61, 66], ["trachea", "ORGAN", 89, 96], ["skin", "ORGAN", 109, 113], ["trachea", "ORGAN", 128, 135], ["spine", "ORGAN", 165, 170], ["skin", "ORGAN", 180, 184], ["curvature", "OBSERVATION_MODIFIER", 44, 53], ["spine", "ANATOMY", 61, 66], ["trachea", "ANATOMY", 89, 96], ["skin", "ANATOMY", 109, 113], ["trachea", "ANATOMY", 128, 135], ["curvature", "OBSERVATION_MODIFIER", 148, 157], ["spine", "ANATOMY", 165, 170], ["skin", "ANATOMY", 180, 184]]], ["CT scans depict that the trachea follows the course of the cervical and thoracic spine and not the direction of the skin contour, and that the curvature of the spine is quite pronounced resulting, the extrathoracic trachea lying deep in the root of neck.", [["trachea", "ANATOMY", 25, 32], ["cervical", "ANATOMY", 59, 67], ["thoracic spine", "ANATOMY", 72, 86], ["skin", "ANATOMY", 116, 120], ["spine", "ANATOMY", 160, 165], ["extrathoracic trachea", "ANATOMY", 201, 222], ["root", "ANATOMY", 241, 245], ["neck", "ANATOMY", 249, 253], ["trachea", "ORGAN", 25, 32], ["cervical", "ORGAN", 59, 67], ["thoracic spine", "MULTI-TISSUE_STRUCTURE", 72, 86], ["skin", "ORGAN", 116, 120], ["spine", "ORGAN", 160, 165], ["extrathoracic trachea", "MULTI-TISSUE_STRUCTURE", 201, 222], ["root", "ORGAN", 241, 245], ["neck", "ORGAN", 249, 253], ["CT scans", "TEST", 0, 8], ["trachea", "ANATOMY", 25, 32], ["cervical", "ANATOMY", 59, 67], ["thoracic spine", "ANATOMY", 72, 86], ["skin", "ANATOMY", 116, 120], ["contour", "OBSERVATION_MODIFIER", 121, 128], ["curvature", "OBSERVATION_MODIFIER", 143, 152], ["spine", "ANATOMY", 160, 165], ["pronounced", "OBSERVATION", 175, 185], ["extrathoracic", "ANATOMY_MODIFIER", 201, 214], ["trachea", "ANATOMY", 215, 222], ["deep", "ANATOMY_MODIFIER", 229, 233], ["root", "ANATOMY_MODIFIER", 241, 245], ["neck", "ANATOMY", 249, 253]]], ["The size discrepancy and curvature mismatch between a standard-size tracheostomy tube and the increased distance between the skin and trachea makes the tracheostomy difficult.", [["skin", "ANATOMY", 125, 129], ["trachea", "ANATOMY", 134, 141], ["tube", "TISSUE", 81, 85], ["skin", "ORGAN", 125, 129], ["trachea", "ORGAN", 134, 141], ["The size discrepancy", "PROBLEM", 0, 20], ["curvature mismatch", "PROBLEM", 25, 43], ["a standard-size tracheostomy tube", "TREATMENT", 52, 85], ["the increased distance between the skin and trachea", "PROBLEM", 90, 141], ["the tracheostomy", "TREATMENT", 148, 164], ["size", "OBSERVATION_MODIFIER", 4, 8], ["discrepancy", "OBSERVATION_MODIFIER", 9, 20], ["curvature", "OBSERVATION_MODIFIER", 25, 34], ["mismatch", "OBSERVATION_MODIFIER", 35, 43], ["size", "OBSERVATION_MODIFIER", 63, 67], ["tracheostomy tube", "OBSERVATION", 68, 85], ["increased", "OBSERVATION_MODIFIER", 94, 103], ["distance", "OBSERVATION_MODIFIER", 104, 112], ["skin", "ANATOMY", 125, 129], ["trachea", "ANATOMY", 134, 141], ["tracheostomy", "OBSERVATION", 152, 164]]], ["As most commercially available tracheostomy tubes are designed with normal limits of anatomic proportions in mind, these standard tubes are usually of inadequate length to suit obese patients and those with short, thick necks [11].DiscussionSurgical emphysema create the situation similar to the obesity with increased skin tracheal distance.", [["skin tracheal", "ANATOMY", 319, 332], ["emphysema", "DISEASE", 250, 259], ["obesity", "DISEASE", 296, 303], ["patients", "ORGANISM", 183, 191], ["skin tracheal", "MULTI-TISSUE_STRUCTURE", 319, 332], ["patients", "SPECIES", 183, 191], ["tracheostomy tubes", "TREATMENT", 31, 49], ["these standard tubes", "TREATMENT", 115, 135], ["short, thick necks", "PROBLEM", 207, 225], ["DiscussionSurgical emphysema", "PROBLEM", 231, 259], ["the obesity", "PROBLEM", 292, 303], ["increased skin tracheal distance", "PROBLEM", 309, 341], ["tracheostomy tubes", "OBSERVATION", 31, 49], ["tubes", "OBSERVATION", 130, 135], ["emphysema", "OBSERVATION", 250, 259], ["obesity", "OBSERVATION", 296, 303], ["increased", "OBSERVATION_MODIFIER", 309, 318], ["skin tracheal", "ANATOMY", 319, 332], ["distance", "ANATOMY_MODIFIER", 333, 341]]], ["But extracare to be taken not to exaggerate the injury already sustained in the larynx and trachea.", [["larynx", "ANATOMY", 80, 86], ["trachea", "ANATOMY", 91, 98], ["larynx", "ORGAN", 80, 86], ["trachea", "ORGAN", 91, 98], ["the injury", "PROBLEM", 44, 54], ["injury", "OBSERVATION", 48, 54], ["larynx", "ANATOMY", 80, 86], ["trachea", "ANATOMY", 91, 98]]], ["In the morbidly obese population, the incidence of complications from tracheostomy has been reported to be approximately 25% with an estimated mortality of 2%, attributed mainly to the loss of airway accessibility [12].", [["airway", "ANATOMY", 193, 199], ["airway", "MULTI-TISSUE_STRUCTURE", 193, 199], ["complications", "PROBLEM", 51, 64], ["tracheostomy", "TREATMENT", 70, 82], ["the loss of airway accessibility", "PROBLEM", 181, 213], ["morbidly", "OBSERVATION_MODIFIER", 7, 15], ["obese", "OBSERVATION_MODIFIER", 16, 21], ["population", "OBSERVATION", 22, 32], ["complications", "OBSERVATION", 51, 64], ["tracheostomy", "OBSERVATION", 70, 82], ["airway", "ANATOMY", 193, 199]]], ["Suction catheters, nasogastric tubes, endotracheal tube exchangers, guidewires, and Eschmann tracheal tube introducers have all been variously used in the management of difficult tracheostomy tube insertion [13].", [["Suction", "ANATOMY", 0, 7], ["tube", "TISSUE", 192, 196], ["Suction catheters", "TREATMENT", 0, 17], ["nasogastric tubes", "TREATMENT", 19, 36], ["endotracheal tube exchangers", "TREATMENT", 38, 66], ["guidewires", "TREATMENT", 68, 78], ["Eschmann tracheal tube introducers", "TREATMENT", 84, 118], ["difficult tracheostomy tube insertion", "TREATMENT", 169, 206], ["catheters", "OBSERVATION", 8, 17], ["nasogastric tubes", "OBSERVATION", 19, 36], ["endotracheal tube", "OBSERVATION", 38, 55], ["tracheal", "ANATOMY", 93, 101], ["tube", "OBSERVATION", 102, 106], ["tracheostomy tube", "OBSERVATION", 179, 196]]], ["In morbidly obese patients, cervical lipectomy or \u201cdefatting\u201d tracheostomy have been successfully employed to access the trachea prior to tracheostomy [14].", [["cervical", "ANATOMY", 28, 36], ["trachea", "ANATOMY", 121, 128], ["patients", "ORGANISM", 18, 26], ["cervical", "ORGAN", 28, 36], ["trachea", "ORGAN", 121, 128], ["patients", "SPECIES", 18, 26], ["cervical lipectomy", "TREATMENT", 28, 46], ["\u201cdefatting", "TREATMENT", 50, 60], ["tracheostomy", "TREATMENT", 62, 74], ["tracheostomy", "TREATMENT", 138, 150], ["morbidly", "OBSERVATION_MODIFIER", 3, 11], ["obese", "OBSERVATION", 12, 17], ["cervical", "ANATOMY", 28, 36], ["lipectomy", "OBSERVATION", 37, 46], ["trachea", "ANATOMY", 121, 128], ["tracheostomy", "OBSERVATION", 138, 150]]], ["Adjustable length tracheostomy tubes, which can be adjusted according to the depth to which the tube is inserted, and extra length tubes with spiral wire reinforced flexible design, are now available for use in the morbidly obese patients [15].DiscussionIntubation carries the risk of retropharyngeal abscess rupture.", [["tube", "ANATOMY", 96, 100], ["retropharyngeal abscess", "ANATOMY", 285, 308], ["abscess rupture", "DISEASE", 301, 316], ["tube", "TISSUE", 96, 100], ["patients", "ORGANISM", 230, 238], ["retropharyngeal abscess", "PATHOLOGICAL_FORMATION", 285, 308], ["patients", "SPECIES", 230, 238], ["Adjustable length tracheostomy tubes", "TREATMENT", 0, 36], ["the tube", "TREATMENT", 92, 100], ["extra length tubes", "TREATMENT", 118, 136], ["spiral wire reinforced flexible design", "TREATMENT", 142, 180], ["retropharyngeal abscess rupture", "PROBLEM", 285, 316], ["length", "OBSERVATION_MODIFIER", 11, 17], ["tracheostomy tubes", "OBSERVATION", 18, 36], ["tube", "OBSERVATION", 96, 100], ["retropharyngeal", "ANATOMY", 285, 300], ["abscess", "OBSERVATION", 301, 308]]], ["In difficult cases tracheostomy under local anaesthesia is safe and reliable method to stabilize airway though the distortion of tissue planes and tracheal deviation due to abscess cavity can make the tracheostomy difficult.", [["airway", "ANATOMY", 97, 103], ["tissue", "ANATOMY", 129, 135], ["tracheal", "ANATOMY", 147, 155], ["abscess cavity", "ANATOMY", 173, 187], ["abscess", "DISEASE", 173, 180], ["airway", "MULTI-TISSUE_STRUCTURE", 97, 103], ["tissue", "TISSUE", 129, 135], ["tracheal", "MULTI-TISSUE_STRUCTURE", 147, 155], ["abscess cavity", "PATHOLOGICAL_FORMATION", 173, 187], ["local anaesthesia", "TREATMENT", 38, 55], ["the distortion of tissue planes", "PROBLEM", 111, 142], ["tracheal deviation", "PROBLEM", 147, 165], ["abscess cavity", "PROBLEM", 173, 187], ["the tracheostomy", "TREATMENT", 197, 213], ["airway", "ANATOMY", 97, 103], ["tracheal", "ANATOMY", 147, 155], ["deviation", "OBSERVATION", 156, 165], ["abscess", "OBSERVATION", 173, 180]]], ["If abscess extended to central compartment it is best to avoid the tracheostomy as pus may trickle into stoma [16].DiscussionPaediatric tracheostomy itself is difficult as having different anatomy from the adult and especially, in the neonate.", [["abscess", "ANATOMY", 3, 10], ["central compartment", "ANATOMY", 23, 42], ["pus", "ANATOMY", 83, 86], ["stoma", "ANATOMY", 104, 109], ["abscess", "DISEASE", 3, 10], ["abscess", "PATHOLOGICAL_FORMATION", 3, 10], ["central compartment", "MULTI-TISSUE_STRUCTURE", 23, 42], ["neonate", "ORGANISM", 235, 242], ["abscess", "PROBLEM", 3, 10], ["the tracheostomy", "TREATMENT", 63, 79], ["pus", "PROBLEM", 83, 86], ["Paediatric tracheostomy", "TREATMENT", 125, 148], ["abscess", "OBSERVATION", 3, 10], ["central", "ANATOMY_MODIFIER", 23, 30], ["tracheostomy", "OBSERVATION", 67, 79], ["stoma", "OBSERVATION", 104, 109], ["tracheostomy", "OBSERVATION", 136, 148], ["neonate", "ANATOMY", 235, 242]]], ["In diphtheria, intubation carries the risk of complete airway occlusion by dislodged membrane along with bleeding into tracheal lumen, though intubation was discovered by Eugene Bouchut in 1858 for bypassing the diphtheria pseudomembrane to the opened airway [17, 18].", [["airway", "ANATOMY", 55, 61], ["membrane", "ANATOMY", 85, 93], ["tracheal lumen", "ANATOMY", 119, 133], ["airway", "ANATOMY", 252, 258], ["diphtheria", "DISEASE", 3, 13], ["airway occlusion", "DISEASE", 55, 71], ["bleeding", "DISEASE", 105, 113], ["airway", "MULTI-TISSUE_STRUCTURE", 55, 61], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["tracheal lumen", "MULTI-TISSUE_STRUCTURE", 119, 133], ["airway", "MULTI-TISSUE_STRUCTURE", 252, 258], ["diphtheria", "PROBLEM", 3, 13], ["intubation", "TREATMENT", 15, 25], ["complete airway occlusion", "PROBLEM", 46, 71], ["dislodged membrane", "PROBLEM", 75, 93], ["bleeding into tracheal lumen", "PROBLEM", 105, 133], ["intubation", "TREATMENT", 142, 152], ["the diphtheria pseudomembrane", "PROBLEM", 208, 237], ["airway", "ANATOMY", 55, 61], ["occlusion", "OBSERVATION", 62, 71], ["dislodged membrane", "OBSERVATION", 75, 93], ["bleeding", "OBSERVATION", 105, 113], ["tracheal", "ANATOMY", 119, 127], ["lumen", "ANATOMY_MODIFIER", 128, 133], ["airway", "ANATOMY", 252, 258]]], ["It is unfortunate to do tracheostomy in vaccine preventable disease, but adequate treatment may lead to successful decannulation.ConclusionSurgical tracheostomy is the dictum for the maintainance of airway in life threatening situations with difficult airway.", [["airway", "ANATOMY", 199, 205], ["airway", "ANATOMY", 252, 258], ["airway", "MULTI-TISSUE_STRUCTURE", 199, 205], ["airway", "MULTI-TISSUE_STRUCTURE", 252, 258], ["tracheostomy", "TREATMENT", 24, 36], ["preventable disease", "PROBLEM", 48, 67], ["adequate treatment", "TREATMENT", 73, 91], ["successful decannulation", "TREATMENT", 104, 128], ["ConclusionSurgical tracheostomy", "TREATMENT", 129, 160], ["difficult airway", "PROBLEM", 242, 258], ["decannulation", "OBSERVATION", 115, 128], ["tracheostomy", "OBSERVATION", 148, 160], ["airway", "ANATOMY", 199, 205], ["airway", "ANATOMY", 252, 258]]], ["Difficult anatomy and the related complications need to be anticipated and appropriate measures to be taken in such emergency situations.", [["Difficult anatomy", "PROBLEM", 0, 17], ["the related complications", "PROBLEM", 22, 47]]]], "3ccd1854942f5ee4133adf536e8962559831a58f": [["To date, the world perhaps has never waited for the summer so impatiently in the 32 entire Anthropocene, owing to the debate whether increasing temperature and 33 humidity will decrease the environmental endurance of SARS-CoV-2.", [["SARS", "DISEASE", 217, 221], ["SARS-CoV", "SPECIES", 217, 225], ["increasing temperature", "PROBLEM", 133, 155]]], ["We present the 34 perspective on the seasonal change on SARS-CoV-2 decay and COVID-19 spread.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["COVID", "TEST", 77, 82]]], ["Our 35 arguments are based on: i) structural similarity of coronavirus with several enteric 36 viruses, and its vulnerability; ii) reports related to decay of those similar transmissible 37 gastroenteritis viruses (TGEV) like norovirus and iii) improvement in the human 38 immunity during summer with respect to winter.", [["coronavirus", "DISEASE", 59, 70], ["gastroenteritis", "DISEASE", 190, 205], ["coronavirus", "ORGANISM", 59, 70], ["transmissible 37 gastroenteritis viruses", "ORGANISM", 173, 213], ["TGEV", "ORGANISM", 215, 219], ["human", "ORGANISM", 264, 269], ["human", "SPECIES", 264, 269], ["TGEV", "SPECIES", 215, 219], ["human", "SPECIES", 264, 269], ["coronavirus", "PROBLEM", 59, 70], ["several enteric 36 viruses", "PROBLEM", 76, 102], ["those similar transmissible 37 gastroenteritis viruses", "PROBLEM", 159, 213], ["norovirus", "PROBLEM", 226, 235], ["coronavirus", "OBSERVATION", 59, 70], ["gastroenteritis viruses", "OBSERVATION", 190, 213]]], ["We present reasons why we can be 39 optimistic about the slowdown of corona in the upcoming summer.", [["corona", "ANATOMY_MODIFIER", 69, 75]]]]}